WO2022246055A1 - Procédé d'optimisation d'une recette de remplissage pour un récipient de médicament - Google Patents
Procédé d'optimisation d'une recette de remplissage pour un récipient de médicament Download PDFInfo
- Publication number
- WO2022246055A1 WO2022246055A1 PCT/US2022/030014 US2022030014W WO2022246055A1 WO 2022246055 A1 WO2022246055 A1 WO 2022246055A1 US 2022030014 W US2022030014 W US 2022030014W WO 2022246055 A1 WO2022246055 A1 WO 2022246055A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- degrees
- vial
- pump
- fill
- setting
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 125
- 239000003814 drug Substances 0.000 title description 13
- 229940079593 drug Drugs 0.000 title description 7
- 230000008569 process Effects 0.000 claims abstract description 47
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 77
- 229940126534 drug product Drugs 0.000 claims description 75
- 238000004519 manufacturing process Methods 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 230000002572 peristaltic effect Effects 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 5
- 229940126586 small molecule drug Drugs 0.000 claims description 5
- 229940125385 biologic drug Drugs 0.000 claims description 4
- 229950000128 lumiliximab Drugs 0.000 description 58
- 102000004169 proteins and genes Human genes 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 51
- 239000000945 filler Substances 0.000 description 21
- 238000005457 optimization Methods 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 108010074604 Epoetin Alfa Proteins 0.000 description 14
- 102100034980 ICOS ligand Human genes 0.000 description 8
- 229960003388 epoetin alfa Drugs 0.000 description 8
- -1 mAb Proteins 0.000 description 8
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
- 108010029961 Filgrastim Proteins 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 230000010437 erythropoiesis Effects 0.000 description 6
- 229960001972 panitumumab Drugs 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 5
- 102100036509 Erythropoietin receptor Human genes 0.000 description 5
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 5
- 108010002601 epoetin beta Proteins 0.000 description 5
- 229960004579 epoetin beta Drugs 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- 108010044644 pegfilgrastim Proteins 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- 108010019673 Darbepoetin alfa Proteins 0.000 description 4
- 108010008165 Etanercept Proteins 0.000 description 4
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 4
- 101710093458 ICOS ligand Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 239000003173 antianemic agent Substances 0.000 description 4
- 108010067416 epoetin delta Proteins 0.000 description 4
- 229950002109 epoetin delta Drugs 0.000 description 4
- 108010081679 epoetin theta Proteins 0.000 description 4
- 229950008826 epoetin theta Drugs 0.000 description 4
- 108010030868 epoetin zeta Proteins 0.000 description 4
- 229950005185 epoetin zeta Drugs 0.000 description 4
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005429 filling process Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 3
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 3
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 3
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 3
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 108010084052 continuous erythropoietin receptor activator Proteins 0.000 description 3
- 229960004177 filgrastim Drugs 0.000 description 3
- 102000044389 human CD22 Human genes 0.000 description 3
- 229940071846 neulasta Drugs 0.000 description 3
- 229940029345 neupogen Drugs 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 108010017584 romiplostim Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102100034608 Angiopoietin-2 Human genes 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 2
- 238000012369 In process control Methods 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 108010042215 OX40 Ligand Proteins 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 101710148535 Thrombopoietin receptor Proteins 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 108010023082 activin A Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940115115 aranesp Drugs 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 2
- 238000012777 commercial manufacturing Methods 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 229960005029 darbepoetin alfa Drugs 0.000 description 2
- 229960001251 denosumab Drugs 0.000 description 2
- 229940073621 enbrel Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940089118 epogen Drugs 0.000 description 2
- 229950009760 epratuzumab Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 2
- 238000010965 in-process control Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010010648 interferon alfacon-1 Proteins 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- 229960000994 lumiracoxib Drugs 0.000 description 2
- 229950001869 mapatumumab Drugs 0.000 description 2
- 229940029238 mircera Drugs 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 108010046821 oprelvekin Proteins 0.000 description 2
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 2
- 229960001373 pegfilgrastim Drugs 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 229950008461 talimogene laherparepvec Drugs 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 229950001212 volociximab Drugs 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- UHTZABZWCSJMDY-UHFFFAOYSA-N 2-(chloromethyl)oxirane;n,n,n',n'-tetrakis(3-aminopropyl)butane-1,4-diamine Chemical compound ClCC1CO1.NCCCN(CCCN)CCCCN(CCCN)CCCN UHTZABZWCSJMDY-UHFFFAOYSA-N 0.000 description 1
- PFWVGKROPKKEDW-UHFFFAOYSA-N 2-[4-[4-(tert-butylcarbamoyl)-2-[(2-chloro-4-cyclopropylphenyl)sulfonylamino]phenoxy]-5-chloro-2-fluorophenyl]acetic acid Chemical compound C=1C=C(C2CC2)C=C(Cl)C=1S(=O)(=O)NC1=CC(C(=O)NC(C)(C)C)=CC=C1OC1=CC(F)=C(CC(O)=O)C=C1Cl PFWVGKROPKKEDW-UHFFFAOYSA-N 0.000 description 1
- HPNRHPKXQZSDFX-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[6-amino-2-[[52-[[2-[[2-[[2-[[5-amino-2-[[2-[[2-[[6-amino-2-[[1-(2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl]amino]hexanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-40-(4-aminobutyl)-49-benzyl-28-butan-2-yl-31,43-bis(3-carbamimidamidopropyl)-34-(carboxymethyl)-16,19,22,25-tetrakis(hydroxymethyl)-10-(2-methylpropyl)-37-(2-methylsulfanylethyl)-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51-hexadecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50-hexadecazacyclotripentacontane-4-carbonyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound N1C(=O)C(NC(=O)CNC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C2N(CCC2)C(=O)C(N)CO)C(C)C)CSSCC(C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2N=CNC=2)C(O)=O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(N)=N)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C1CC1=CC=CC=C1 HPNRHPKXQZSDFX-UHFFFAOYSA-N 0.000 description 1
- MZZYGYNZAOVRTG-UHFFFAOYSA-N 2-hydroxy-n-(1h-1,2,4-triazol-5-yl)benzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=NC=NN1 MZZYGYNZAOVRTG-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000018746 Apelin Human genes 0.000 description 1
- 108010052412 Apelin Proteins 0.000 description 1
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 1
- 229960005509 CAT-3888 Drugs 0.000 description 1
- 229940124296 CD52 monoclonal antibody Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100179591 Caenorhabditis elegans ins-22 gene Proteins 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000014468 Calcitonin Gene-Related Peptide Receptors Human genes 0.000 description 1
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 102100033183 Epithelial membrane protein 1 Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101150043052 Hamp gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
- 101000850989 Homo sapiens Epithelial membrane protein 1 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001010568 Homo sapiens Interleukin-11 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101150030083 PE38 gene Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 101710182223 Toxin B Proteins 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002691 anti-thymic effect Effects 0.000 description 1
- BWVPHIKGXQBZPV-QKFDDRBGSA-N apelin Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCSC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 BWVPHIKGXQBZPV-QKFDDRBGSA-N 0.000 description 1
- 229950009925 atacicept Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960003270 belimumab Drugs 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229950007940 bixalomer Drugs 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 229940101815 blincyto Drugs 0.000 description 1
- 229950005042 blosozumab Drugs 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229950007296 cantuzumab mertansine Drugs 0.000 description 1
- 108700001003 carbamylated erythropoietin Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229940090100 cimzia Drugs 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 1
- 229960002224 eculizumab Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229940102709 ferumoxytol Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229950001109 galiximab Drugs 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 229940063135 genotropin Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 108010013846 hematide Proteins 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 102000049885 human IL11 Human genes 0.000 description 1
- 102000053529 human TNFSF11 Human genes 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 229940065770 humatrope Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 229960003358 interferon alfacon-1 Drugs 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 229940032961 iron sucrose Drugs 0.000 description 1
- 229940054136 kineret Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229950010470 lerdelimumab Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940076783 lucentis Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 229960001046 methoxy polyethylene glycol-epoetin beta Drugs 0.000 description 1
- 229950000720 moxetumomab pasudotox Drugs 0.000 description 1
- 229960003816 muromonab-cd3 Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229940054205 natrecor Drugs 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229940082926 neumega Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229950005751 ocrelizumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 229940035567 orencia Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960000402 palivizumab Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 108010048732 pegylated erythropoietin Proteins 0.000 description 1
- 229950003203 pexelizumab Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 229940092597 prolia Drugs 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 229950010968 romosozumab Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 229940116949 sensipar Drugs 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940036185 synagis Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950001210 trebananib Drugs 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229950009578 vidupiprant Drugs 0.000 description 1
- 229950004393 visilizumab Drugs 0.000 description 1
- 229940014556 xgeva Drugs 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 229950009002 zanolimumab Drugs 0.000 description 1
- 229940051223 zetia Drugs 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
- B65B3/10—Methods of, or means for, filling the material into the containers or receptacles by application of pressure to material
- B65B3/12—Methods of, or means for, filling the material into the containers or receptacles by application of pressure to material mechanically, e.g. by pistons or pumps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/26—Methods or devices for controlling the quantity of the material fed or filled
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B3/26—Methods or devices for controlling the quantity of the material fed or filled
- B65B3/28—Methods or devices for controlling the quantity of the material fed or filled by weighing
Definitions
- the present disclosure generally relates to filling recipes for drug containers and, more particularly, to a universal method of optimizing a filling recipe for a drug container.
- existing fill recipes are individually tailored to a single drug product, each of which has a unique filling process and set of operating parameters.
- a pump in a manufacturing facility carrying out the filling recipe must be calibrated each time a new filling recipe is needed for a new drug product.
- the time involved to calibrate the pump or related equipment in a manufacturing facility before beginning the filling process according to a particular filling recipe is often lengthy. For example, there are typically many cycles needed, such as multiple number of strokes of the pump, until the pump is able to operate according to a particular filling recipe.
- a method of filling a vial comprises providing a pump corresponding to a vial, and setting a drip retraction parameter for the pump to any value equal to or less than 20 degrees.
- the method further comprises setting a no adjustment limit for a fill weight of the vial to T1 , with T 1 being at or in a range of about 2% more or less than a fill weight of a target fill weight TO, and wherein a process performance index Cpk (Cpk) for the vial throughout a fill cycle exceeds a minimum value.
- a method of filling a plurality of vials of a nested syringe and vial line comprises providing a plurality of pumps corresponding to a plurality of vials of a nested syringe and vial line, and setting a drip retraction parameter for each pump in the plurality of pumps to any value equal to or less than 20 degrees.
- the method also includes filling each vial of the plurality of vials with a drug product via a corresponding pump of the plurality of pumps; and wherein a Cpk for each vial of the plurality of vials exceeds a minimum value throughout a fill cycle.
- a method of optimizing a filling recipe for a nested syringe and vial line comprises setting a drip retraction parameter for at least one pump in an offline manufacturing system corresponding to any value equal to or less than 20 degrees, and monitoring a performance of the at least one pump with the drip retraction parameter of the at least one pump set to any value equal to or less than 20 degrees.
- the method also includes obtaining at least a minimum value for a Cpk for the at least one container throughout at least one fill cycle and for at least one drug product using the at least one pump in the offline manufacturing system; and finalizing a filling recipe for a nested syringe and vial line using data from fill cycles of the at least one drug product using the at least one pump in the offline manufacturing system.
- a method of filling a vial may comprise providing a pump corresponding to a vial, setting a drip retraction parameter for the pump to any value equal to or less than 20 degrees, and setting a no adjustment limit for a fill weight of the vial to any value within a range of a target fill weight TO and T1 , with T 1 being at or in a range between the target fill weight TO and T2. So configured, a minimum value for a process performance index Cpk (Cpk) for the vial throughout a fill cycle is exceeded.
- Cpk process performance index
- setting a drip retraction parameter for the pump to any value equal to or less than 20 degrees may comprise setting the drip retraction parameter for the pump to one of 10 degrees, 20 degrees, or any value in a range of 10 degrees to 20 degrees.
- the method may further comprise setting an end drip retraction value to 290 degrees when setting the drip retraction parameter to 20 degrees or setting an end drip retraction value to 280 degrees when setting the drip retraction parameter to 10 degrees.
- providing a pump corresponding to a vial may comprise providing a pump corresponding to a vial of a nested syringe and vial line.
- providing a pump corresponding to a vial may comprise providing one or more of a first fill set or a second fill set, the first fill set including a peristaltic pump filling assembly having a needle with an outer diameter of about 2.0mm, and the second fill set including a peristaltic pump filling assembly having a needle with an outer diameter of about 3.0mm.
- a Cpk for the vial exceeds a minimum value throughout a fill cycle may comprise one or more of: (1) the Cpk for the vial exceeds a value of 1.33; or (2) the Cpk for the vial exceeds the minimum value during a temperature range throughout the fill cycle, the temperature range is one of: (1) 5 (+/-3) degrees Celsius; (2) 20 (+/-5) degrees Celsius; or (3) 10 to 19 degrees Celsius.
- the method may further comprise filling the vial with a drug product via the pump, wherein the drug product has one or more of the following characteristics: (a) a density in a range of about 1.0-1.2 g/cm 3 ; (b) a viscosity in a range of about 1.0-10.0 cP; and (c) a surface tension in a range of about 40.0-72.7 mN/m.
- the drug product has a density in a range of 1.0-1.2 g/cm3; a viscosity in a range of about 1.0-10.0 cP; and a surface tension in a range of about 40.0- 72.7 mN/m.
- the drug product comprises a biologic drug (e.g., peptides, mAb, siRNA) or a small molecule drug.
- the method may further comprise monitoring a performance of the filling recipe in the nested syringe and vial line and obtaining at least a minimum value for the Cpk for the at least one container for each pump in a plurality of pumps in the nested syringe and vial line.
- FIG. 1 is a schematic representation of one embodiment of an offline filling system utilizing a filling recipe of the present disclosure
- FIG. 2A is a perspective view of a filler of the system of FIG. 1 ;
- FIG. 2B is a portion of the filler of FIG. 2A;
- FIG. 2C is a perspective view of a fill set of the system of FIG. 1 ;
- FIG. 2D is a perspective view of another fill set of the system of FIG. 1 ;
- FIG. 2E is a perspective view of an exemplary fill target of the system of FIG. 1 ;
- FIG. 3A is a chart depicting parameters of each of the fill sets of FIG. 1;
- FIG. 3B is a chart depicting in process control parameters of the fill sets of FIG. 1 ;
- FIG. 3C is a chart depicting product characteristics of drug products for use with the methods of the present disclosure.
- FIG. 4 is a flow chart depicting a filling recipe parameter optimization strategy relative to the filling recipe of the present disclosure
- FIG. 5A is a perspective view of fill performance results of a vial after filling at various drip retraction values
- FIG. 5B is a chart depicting aspects of an exemplary fill recipe used with the fill performance results of FIG. 5A;
- FIG. 6A depicts an exemplary filling recipe according to one aspect of the present disclosure
- FIG. 6B is a graph depicting filling performance results of the filling recipe of FIG. 6A;
- FIG. 6C is a chart depicting the filling performance results of the graph of FIG. 6B;
- FIG. 7A is a chart depicting needle parameters of a needle used with a filling recipe of the present disclosure
- FIG. 7B is a chart depicting pump parameters of at least one pump used with a filling recipe of the present disclosure
- FIG. 8A is a graph depicting filling performance results of the filling recipe of the present disclosure in a temperature range of 10 - 11 degrees Celsius and using a second fill set of the system of FIG. 1;
- FIG. 8B is a chart depicting the filling performance results of the graph of FIG. 8A;
- FIG. 9A is a graph depicting the filling performance results of the filling recipe of the present disclosure at a temperature of about 19 degrees Celsius and using the second fill set of the system of FIG. 1;
- FIG. 9B is a chart depicting the filling performance results of the graph of FIG. 9A;
- FIG. 10A is a graph depicting the filling performance results of the filling recipe of the present disclosure at a temperature of about 10-11 degrees Celsius and using the first fill set of the system of FIG. 1;
- FIG. 10B is a chart depicting the filling performance results of the graph of FIG. 10A;
- FIG. 11A is a graph depicting the filling performance results of the filling recipe of the present disclosure at a temperature of about 19 degrees Celsius and using the first fill set of the system of FIG. 1;
- FIG. 11 B is a chart depicting the filling performance results of the graph of FIG. 11 A;
- FIG. 12 is a schematic representation of a manufacturing line in a manufacturing plant using the optimized filling recipe of the present disclosure
- FIG. 13A is a perspective view of a nested syringe and vial line of the manufacturing line of FIG. 12;
- FIG. 13B is a schematic view of the nested syringe and vial line of FIG. 13A;
- FIG. 13C is a perspective view of a plurality of pumps corresponding to a plurality of vials of the nested syringe and vial line of FIGS. 13A-13B;
- FIG. 14 is a chart depicting filling performance results of the filling recipe of the present disclosure in at least one of the nested syringe and vial line of FIG. 12;
- FIG. 15 is a chart depicting filling performance results of a previously used filling recipe used in a nested syringe and vial line.
- an efficient filling recipe for filling formulations comprising therapeutic proteins in a nested syringe and vial line is disclosed.
- the universal filling recipe include a drip retraction parameter optimization within a specified value, which results in a significantly more efficient fill recipe compared to other existing, known filling recipes.
- the new filling recipe of the present disclosure may be used with many different drug products and results in 95% reduction in fill weight optimization cycles. This led to an improvement of 10-30% increase utilization of a nested syringe and vial line fill time and potentially saving a significant number of units, such as vials, from rejection.
- the drug products referred to herein comprise therapeutic proteins, such as monoclonal antibodies, as explained more below.
- the offline manufacturing system 10 is a small scale bench set-up in a pilot facility, which made various tests related to the new filling recipe easier to assess and update based on test results for various attempted recipes, for example.
- the offline manufacturing system 10 includes a filler 12, a first fill set 14, and a second fill set 16.
- the first fill set 14 includes a corresponding first fill target 18, such as a vial
- the second fill set 16 likewise includes a corresponding second fill target 20, also such as a vial.
- the filler 12 is a Bausch+Strobel (B&S) scale-down filler in which recipe optimization, including many experiments, were conducted before arriving at the optimal, universal filling recipe of the present disclosure. While the specific B&S scale-down filler was used, it will be appreciated that various other fillers may also or alternatively be used.
- B&S scale-down filler was used, it will be appreciated that various other fillers may also or alternatively be used.
- each of the first and second fill targets 18, 20 are referred to as a vial in one example, it will be understood that the fill targets 18, 20 may alternatively and more generally be any other similar drug container and still fall within the scope of the present disclosure.
- the optimal filling recipe selected from the recipe optimization from the scale-down filler 12 and first and second fill sets 12, 16 is transferable to a manufacturing line, such as a nested syringe and vial line in FIGS. 13A and 13B.
- FIGS. 2A-2E a perspective view of each of the filler 12, first and second fill sets 14, 16 and first and second fill targets 18, 20 of FIG. 1 is depicted.
- the filler 12 is a Bausch+Strobel Filler, a bench scale down filler, and more generally a developmental filler to support clinical and commercial manufacturing, as explained more below.
- Exemplary containers that may be used with this filler include bulk ISO 2R, 6R, 20R, 3cc, 5cc, 10cc, 20cc vials, bulk 1mL glass and 1 mL plastic syringes, and bulk 5cc plastic cartridges.
- the filler 12 includes a dosing vessel 21, a pump 22, such as a peristaltic pump, and a product bag 23.
- FIG. 2B depicts a portion of the filler 12 of FIG. 2A.
- the pump 22 is depicted cooperating with a fill target, such as the first fill target 18 or the second fill target 20.
- the first and second fill targets 18, 20 are the same vial, but may also be any other container and still fall within the scope of the present disclosure.
- the first filling set 14 of FIG. 1 is depicted.
- the first filling set 14 is a peristaltic pump and includes a bag 27, tubing 28A, and a needle 29A.
- the tubing 28A is coupled to the bag 27 at one end and the fill target 18 at the other end, such that the fluid in the bag is able to be drawn into the tubing and to the fill target 18 by way of the needle 29A, for example.
- the outer diameter of the needle 29A is 2.0m
- the inner diameter of the needle is 1 6mm
- the inner diameter of the pump tubing 28A is 1.6 mm.
- the tubing 28A branches into two tubing and converges again.
- FIG. 2D depicts the second fill set 16 of FIG. 1.
- the second fill set 16 is a peristaltic pump and includes the bag 27, tubing 28B, and a needle 29B, which is different from the needle 29A of the first fill set 14.
- the tubing 28B is again coupled to the bag 27 at one end and the second fill target 20 at the other end, such that fluid in the bag is able to be drawn through the tubing and into the second fill target 20 by way of the needle 29B.
- the tubing 28B again branches into two tubing and then converges again, but the two tubing have a different inner diameter.
- the inner diameter of the tubing 28B is 1 6mm and 3.2 mm, respectively.
- the outer diameter of the needle 29B is 3.0mm
- the inner diameter of the needle is 2.6mm
- the inner diameter of the pump tubing is 1.6 mm.
- the exemplary fill target may include the first and second fill targets 18, 20 of FIG. 1, for example.
- the first and second fill targets 18, 20 include a 1.3 mL fil in ISO 2R vial.
- the target weight is 1.365 grams
- T2+ is 0.05grams, which is 1.415 grams
- T2- is 0.05 grams, which is 1.315 grams.
- T1+ is 0.03 grams, which is 1.395 grams
- T1- is 0.03 grams, which is 1.335 grams.
- the net weight no adjustment limit + is 0.02 grams, which is 1.385 grams
- the net weight no adjustment limit - is 0.02 grams, which is 1.345 grams.
- the first fill set 14 is a peristaltic pump filling assembly having a needle with an outer diameter of 2.0mm and an inner diameter of 1 6mm.
- the peristaltic pump filling assembly includes tubing (in FIG. 2C) having an inner diameter of 1 6mm.
- the chart in FIG. 3A also includes information about the second fill set 16, which in this example also includes a peristaltic pump filling assembly having a needle with an outer diameter of 2.0mm and an inner diameter of 2.6mm.
- the second fill set 16 also includes tubing having an inner diameter of 1 6mm, and another tubing having an inner diameter of 3.2mm, as mentioned above.
- a no adjustment limit for a fill weight of the second fill target 20, such as the vial was set to T1 , with T 1 being at or in a range of about 2% more or 2% less than a fill weight of a target fill weight TO.
- the target fill weight TO includes a volume of 1.3 mL and a mass of 1.365 grams.
- the no adjustment limit was 80% of T1 , which may be +/- 0.02 grams of T1 +/- 0.03 grams.
- the fill target mass of a vial in which no adjustment is needed is any value in the range of 1.345 grams to 1.385 grams in this example.
- the no adjustment limit for a fill weight of the vial, such as the second fill target 20 may be set to any value within a range of a target fill weight TO and T1 , with T 1 being at or in a range between the target fill weight TO and T2 based on process performance, for example. In some examples, T 1 is set at 2%, but may be changed.
- the filling recipe of the present disclosure includes filling a vial, such as the vials of the first and second filling targets 18, 20, with a drug product via a pump, and the drug product includes a mAb formulation.
- the mAb formulations used are drug product 1 (DP1) and drug product 1 (DP2) As provided in the chart, at 5 degrees Celsius the density of DP1 is 1.055 g/cm 3 and the viscosity is 4.857.
- the density of DP1 is 1.05 g/cm 3 , the viscosity is 2.604 cP, and the surface tension is 41.63 mN/m .
- the density of DP2 is 1.054 g/cm 3 and the viscosity is 4.07 cP.
- the density of DP2 is 1.049 g/cm 3 , the viscosity is 2.19 cP, and the surface tension is 43.716 mN/m .
- the drug product used in the filling recipe is a mAb formulation including one or more of: (1) a density in a range of either about 1.054-1.055 g/cm 3 at 5 degrees Celsius or about 1.049-1.05 g/cm 3 at 25 degrees Celsius;
- the method disclosed herein can be used to fill any liquid drug product, such as drug products comprising a biologic drug (e.g., peptides, mAbs, siRNAs) and a small molecule drug, provided the drug product has a specified physical parameter range.
- the drug product may include one or more of the following characteristics: (1) a density in a range of about 1.0-1.2 g/cm 3 ; and/or (2) a viscosity in a range of about 1.0-10.0 cP; and/or (3) a surface tension in a range of about 40.0-72.7 mN/m.
- preferred ranges for the viscosity are one or more of 1.0-8.0 cP, 1.0-6.0 cP,
- the drug product has a density in a range of 1.0-1.2 g/cm 3 ; a viscosity in a range of about 1.0-10.0 cP; and a surface tension in a range of about 40.0-72.7 mN/m.
- the drug product has one or more of a density in a range of 1.0-1.2 g/cm 3 and a viscosity in a range of about 1.0-10.0 cP, and any value for a surface tension.
- the determining factors for the filling recipe are the density and the viscosity of the drug product, and the filling recipe may work with any surface tension. It will be understood that a drug product meeting any of these parameters may be used with the methods and filling recipe of the present disclosure.
- manufacturing data suggests that a drug product with a viscosity of about 8.0 cP or more worked well with a drip retraction value of 20 degrees.
- the preferred density of the drug product is about 1.0-1.1 g/cm 3 . It will be appreciated that many other values within the density, viscosity, and surface tension ranges provided above may be used for the drug products used with the methods and filling recipes of the present disclosure and fall within the scope of the present disclosure.
- step 30 an initial optimization based on an existing filling recipe, which is referred to as existing filling recipe No. 1, was conducted on the second fill set 16.
- step 32 with this initially optimized DP1 filling recipe for the second fill set 16, a range of drip retraction parameters ranging from 0 degrees to 45 degrees was tested.
- step 34 another existing filling recipe, referred to as existing filling recipe No. 2, was started and a range of drip retraction parameters from 10 degrees to 20 degrees was tested.
- step 36 was then developed in step 36 and various drip retraction parameters were also tested, including 5 degrees, 10 degrees and 20 degrees.
- step 38 the hybrid recipe was finalized for the second fill set 16 with a drip retraction parameter set at 20 degrees.
- step 40 the same filling recipe was used for the first fill set 14 and drip retraction parameters were set at 10 degrees and 20 degrees. Based on the fill performance, a filling recipe for the first fill set 14 was finalized with a drip retraction parameter set at 20 degrees.
- fill performance results of the second fill target 20, such as the vial, of the second fill set 16 after utilizing a filling recipe with various drip retraction values is provided.
- a test was conducted and the fill performance of the vial monitored when the drip retraction parameter of the filling recipe for the pump was set to each of 0 degrees, 10 degrees, 20 degrees, 30 degrees, 40 degrees, and 45 degrees.
- an air gap AG in the fill target 20 or vial increased with increasing drip retraction parameter leading to an air liquid bilayer, explaining a likely reason for poor fill performance when a higher drip retraction parameter is set in the filling recipe.
- FIG. 5A an air gap AG in the fill target 20 or vial increased with increasing drip retraction parameter leading to an air liquid bilayer, explaining a likely reason for poor fill performance when a higher drip retraction parameter is set in the filling recipe.
- the start pump dosing was set at 40 degrees
- the pump dosing start ramp was set at 90 degrees
- the pump dosing stop ramp was set at 210 degrees
- the end pump dosing was set at 260 degrees
- the end drip retraction was set at 310 degrees
- the distance run per dose was 766 degrees.
- the start pump dosing was set at 40 degrees
- the pump dosing start ramp was set at 90 degrees
- the pump dosing stop ramp was set at 210 degrees
- the end pump dosing was set at 260 degrees
- the end drip retraction was set at 290 degrees
- the distance run per dose was 766 degrees.
- the impact of the drip retraction parameter set at 20 degrees on fill performance of DP1 in the second fill set 16 is provided.
- the minimum filling weight was 1.348 grams and the maximum filling weight was 1.384 grams, making the average fill weight 1.366 grams, with a standard deviation of 0.006.
- the process performance index Cpk value was 2.69, which is considerably higher than experiments using a filling recipe with the same parameters except for the drip retraction parameter of 45 degrees. Said another way, the process performance index was much higher when the drip retraction parameter was set to 20 degrees compared to higher values, such as 45 degrees, further indicating the impact of the drip retraction parameter on the fill performance.
- the process performance index Cpk provides a value indicative of the efficiency of a particular process.
- the process performance index value Cpk relates to how close an actual fill weight of a container, such as a vial, is to a target fill weight.
- the process performance index value Cpk also relates to how close each subsequent fill rate of the additional containers, e.g., vials, are to each other. If there is a high number of the process performance index value Cpk, a given pump is providing an optimal performance. Likewise, a low number for the process performance index value Cpk indicates the pump is poorly performing.
- the filling recipe 50 includes specific needle parameters, including setting a needle setting dimension to one of 134.5 mm and 39.0 mm, setting a basic needle position to 7.0 mm, and setting the start needle down to 25 degrees.
- the needle parameters for the filling recipe 50 also include setting the needle at a dosing start of 10 mm, setting the needle down to one of 60 degrees and 23 degrees, and setting the needle up at 125 degrees.
- the filling recipe 50 also includes setting the needle at the end of dosing to 13.0 mm and 310 degrees, setting the start needle to cut-off position of 315 degrees, setting the cut off position reached to 13.0 mm and 315 degrees, setting the start needle to a basic position of 315 degrees, and the basic needle position reached to 359 degrees.
- the finalized filling recipe 50 of the present disclosure also includes setting several parameters for the pump.
- the filling recipe 50 includes setting the start pump dosing to 40 degrees, setting the pump dosing start ramp to 90 degrees, setting the pump dosing stop ramp to 210 degrees, and setting the end pump dosing to 260 degrees.
- the filling recipe includes setting the drip retraction parameter to 20 degrees, such as the pump distance run for the drip retraction to 20 degrees, the end drip retraction parameter to 290 degrees, and the distance run per dose parameter to 766 degrees.
- the filling recipe 50 may include setting the drip retraction parameter to any value equal to or less than 20 degrees and still fall within the scope of the present disclosure.
- the lowest value of the drip retraction parameter is 0 degrees.
- the filling recipe 50 may include setting the drip retraction parameter for the pump to one of 10 degrees, 20 degrees, or any value in a range of 10 degrees to 20 degrees.
- the filling recipe 50 may include setting the end drip retraction to 290 degrees when the drip retraction parameter is set to 20 degrees, or setting the end drip retraction value to 280 when setting the drip retraction parameter to 10 degrees, for example.
- the finalized filling recipe 50 also includes setting a no adjustment limit for the fill weight of any vial to T1 , with T 1 being at or in a range of about 2% more or 2% less than a fill weight of a target fill weight TO, as explained above relative to FIG. 3B, for example.
- the same filling recipe 50 was finalized for the exemplary drug product DP1 in the second fill set 16
- the same filling recipe 50 may also be used for the first fill set 14 using DP1 or other drug products in the mAb formulation programs, for example.
- the same finalized filling recipe 50 is also effectively used for a nested syringe and vial line of a manufacturing plant.
- the method of optimizing a filling recipe for a nested syringe and vial line or other manufacturing line in a manufacturing plant includes using the first and second fill sets 14, 16 of the offline manufacturing system 1 of FIG. 1, for example.
- FIGS. 8A and 8B the impact of temperature on fill performance of the second fill set 16 was evaluated for efficacy and the results are provided in the graph of FIG. 8A and the table of FIG. 8B.
- the temperature was set at 10-11 degrees Celsius and the process performance parameter Cpk during this temperature range of 10-11 degrees Celsius throughout the fill cycle well exceeded a minimum value of 1.33.
- the cycle included 103 fills, with a minimum fill weight of 1.340 g, a maximum fill weight of 1.393 g, and an average fill weight of 1.362 g with a standard deviation of 0.008 grams.
- the process performance parameter Cpk value was 1.95, well above the target minimum value of 1.33, for example. While FIG. 8A shows that occasional filling weights were close to the T 1 limits at this temperature range, subsequent fill weights were able to return close to the target without significantly impacting the process performance index Cpk.
- FIGS. 9A and 9B the impact of a temperature higher than 10-11 degrees Celsius (as in FIGS. 8A and 8B) on fill performance of the second fill set 16 was evaluated, and the results are provided in the graph of FIG. 9A and the table of FIG. 9B.
- the temperature was set at about 19 degrees Celsius, and the process performance parameter Cpk during this temperature of about 19 degrees Celsius throughout the fill cycle well exceeded a minimum value of 1.33.
- the cycle included 103 fills, with a minimum fill weight of 1.348 g, a maximum fill weight of 1.384 g, and an average fill weight of 1.366 g with a standard deviation of 0.006 grams.
- process performance parameter Cpk against T2 was 2.69, well above both the target minimum value of 1.3, and the process performance parameter Cpk for the fill performance at the lower temperature of 10-11 degrees Celsius, in this example. This indicates an even better fill performance for the finalized filling recipe at slightly higher temperatures.
- the impact of a temperature on fill performance of the first fill set 14 was evaluated, and the results are provided in the graph of FIG. 10A and the table of FIG. 10B.
- the temperature was set at about a range of 10-11 degrees Celsius, and the process performance parameter Cpk during this temperature throughout the fill cycle well exceeded a minimum value, such as 1.33.
- the cycle included 100 fills, with a minimum fill weight of 1.354 g, a maximum fill weight of 1.380 g, and an average fill weight of 1.365 g with a standard deviation of 0.005 grams.
- the process performance parameter Cpk against T2 was 3.16, well above each of the target minimum value of 1.33, and the process performance parameter Cpk for the fill performance of the second fill set 16 at both the lower temperature of 10-11 degrees Celsius (FIGS. 8A and 8B) and the higher temperature 19 degrees Celsius (FIGS. 9A and 9B), for example.
- these results further show the universal nature and applicability of the finalized filling recipe on different fill sets, and this filling recipe may also be successfully transferred and used with a nested syringe and vial line of a manufacturing plant, for example.
- FIGS. 11 A and 11 B the impact of a temperature higher than 10-11 degrees Celsius (as in FIGS. 10A and 10B) on fill performance of the first fill set 14 was evaluated, and the results are provided in the graph of FIG. 11A and the table of FIG. 11 B.
- the temperature was set at about 19 degrees Celsius and the process performance parameter Cpk during this temperature of about 19 degrees Celsius throughout the fill cycle well exceeded a minimum value of 1.33.
- the cycle included 120 fills, with a minimum fill weight of 1.352 g, a maximum fill weight of 1.373 g, and an average fill weight of 1.362 g with a standard deviation of 0.004 grams.
- the process performance parameter Cpk against T2 was 3.61 , well above both the target minimum value of 1.33, and the process performance parameter Cpk of 3.16 for the fill performance at the lower temperature of 10-11 degrees Celsius, for example.
- the manufacturing line 102 includes at least one nested syringe and vial line 104 in which the efficient universal filling recipe 50 of the present disclosure is effectively used.
- the nested syringe and vial line 104 is a nested syringe and vial line (NSVL) having a plurality of vials 105, such as ISO 2R RTU vials.
- NSVL nested syringe and vial line
- the filling recipe 50 of the present disclosure may be utilized in a variety of other nested syringe and vial lines and still fall within the scope of the present disclosure.
- the vial 105 may more generally be any container 105, such as a syringe, and still fall within the scope of the present disclosure.
- the manufacturing line 102 may include a plurality of nested syringe and vial lines 106, each of which includes the at least one nested syringe and vial line 104, for example.
- the manufacturing line 102 also includes at least one pump 110 that corresponds to and cooperates with at least one vial of the at least one nested syringe and vial line 104.
- the nested syringe and vial line 104 is a B20 nested syringe and vial line (NSVL) that includes a semi-automated debagger 104a, an automated debagger 104b, a rapid transfer airlock 104c, a nested filler (isolator) 104d, and a capper 104e.
- NSVL B20 nested syringe and vial line
- Various other clinical or commercial manufacturing fillers may alternatively be used and still fall within the scope of the present disclosure.
- FIG. 13B depicts a plurality of pumps, which may be the plurality of pumps 112 that correspond to the plurality of vials 114 of the nested syringe and vial line 104 of FIG. 12, for example.
- the plurality of pumps 112 include five pumps 110 that cooperate with each vial 105 of the plurality of vials 114.
- the nested syringe and vial line 104 is a clinical manufacturing filler, such a Bausch & Strobel filler.
- the containers 105 are referred to generally as vials, it will be understood that the containers 105 may be one or more of vials, syringes or plastic cartridges and still fall within the scope of the present disclosure.
- the containers 105 may include nested ISO 2R vials, nested 1mL glass and plastic syringes, or nested 5cc plastic cartridges.
- the plurality of pumps include five pumps 110 in this example, it will be understood that more or fewer pumps may alternatively be used and still fall within the scope of the present disclosure.
- the plurality of pumps may include 10 pumps or 2 pumps for different filler, or any other number of pumps within this range, for example, and still fall within the scope of the present disclosure.
- a method of filling the plurality of vials 105 of the nested syringe and vial line 104 comprises providing one of the pump 110 or a plurality of pumps 112 corresponding to one of the vial 105 or the plurality of vials 105 of the nested syringe and vial line 104.
- the method also includes setting the drip retraction parameter for each pump 110 to any value equal to or less than 20 degrees.
- the method also includes setting a no adjustment limit for the fill weight of the vial 105 to T 1 , with T 1 being at or in a range of about 2% more or 2% less than the fill weight of the target fill weight TO.
- the method may still further include filling each vial 105 of the plurality of vials 105 with a drug product, such as a mAb formulation, via a corresponding pump 110 of the plurality of pumps 112.
- the method may still also include exceeding a minimum value for the process performance index Cpk for each vial 105 of the plurality of vials 105 during a temperature range throughout a fill cycle, the temperature range one of: (1) 5 (+/-3) degrees Celsius; (2) 20 (+/-5) degree Celsius; or (3) 10 to 19 degrees Celsius.
- the minimum value for the process performance index Cpk is 1.33. In other examples, such as in clinical fills, a minimum value for the process performance index Cpk is 1.0. However, in this example, and as generally understood in commercial fills, the minimum value for the process performance index Cpk is 1.33.
- filling each vial 105 with the drug product via the corresponding pump 110 of the plurality of pumps 112 comprises filling each vial 105 with a drug product, wherein the drug product has one or more of the following characteristics: (1) a density in a range of about 1.0-1.2 g/cm3; (b) a viscosity in a range of about 1.0-10.0 cP; and (c) a surface tension in a range of about 40.0-72.7 mN/m.
- the drug product has a density in a range of 1.0-1.2 g/cm3; a viscosity in a range of about 1.0-10.0 cP; and a surface tension in a range of about 40.0-72.7 mN/m.
- the fill performance of the new filling recipe of the present disclosure in the nested syringe and vial line 104 is provided.
- the total dose optimization cycle such as the number of strokes of the pump 110 (or pumps 112) needed to teach the pump 110 how to operate using the new filling recipe is minimized.
- the total dose optimization cycle value is 4, which is significantly reduced compared to values of the total dose optimization cycle of previous filling recipes set forth in FIG. 15, for example.
- the process performance index Cpk for each nozzle (not shown) of each pump 110 of the plurality of pumps 112 of the nested syringe and vial Iine104 exceeds the minimum value of 1.33 for the process performance index Cpk desired.
- the average process performance index Cpk value for all nozzles of the pumps 110 is 1.4.
- FIG. 15 a chart listing the process performance index Cpk of nozzles of the pumps using old filling recipes is set forth. Specifically, when using old filling recipes for a large variety of different drug products, including the mAb formulations, the average process performance index Cpk for all nozzles of the pumps was well below the desired process performance index Cpk value of 1 .33. Said another way, all of the process performance index Cpk values were less than 1.33.
- the total dose optimization cycle was greater for each drug product using the old filling recipe compared to the dose optimization cycle value listed in FIG. 14 when using the new filling recipe 50.
- the method of optimizing the filling recipe for the nested syringe and vial line 104 includes setting the drip retraction parameter for at least one pump 14, 16, 22 in the offline manufacturing system 10 corresponding to at least one container 18, 20 to any value equal to or less than 20 degrees.
- the method further includes monitoring a performance of the at least one pump 14, 16, 20 with the drip retraction parameter of the at least one pump 14, 16, 22 set to any value equal to or less than 20 degrees.
- the method still further includes obtaining at least a minimum value for the process performance index (Cpk) for the at least one container 18, 20 throughout at least one fill cycle and for at least one drug product using the at least one pump 14, 16, 22 in the offline manufacturing system 10.
- the method also includes finalizing a filling recipe for the nested syringe and vial line 104 using data from fill cycles of the at least one drug product using the at least one pump 14, 16, 22 in the offline manufacturing system 10.
- the above description describes various systems and methods of filling a vial of a nested syringe and vial line. It should be clear that the system or methods can further comprise use of a medicament listed below with the caveat that the following list should neither be considered to be all inclusive nor limiting.
- the medicament will be contained in a reservoir.
- the reservoir is a primary container that is either filled for treatment with the medicament.
- the primary container can be a vial, a cartridge or a syringe.
- drug products that may be used with the methods disclosed herein may include colony stimulating factors, such as granulocyte colony-stimulating factor (G-CSF).
- G-CSF agents include, but are not limited to, Neupogen® (filgrastim) and Neulasta® (pegfilgrastim).
- the methods may use various pharmaceutical products, such as an erythropoiesis stimulating agent (ESA), which may be in a liquid or a lyophilized form.
- ESA erythropoiesis stimulating agent
- An ESA is any molecule that stimulates erythropoiesis, such as Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxy polyethylene glycol-epoetin beta), Flematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo®
- An ESA can be an erythropoiesis stimulating protein.
- erythropoiesis stimulating protein means any protein that directly or indirectly causes activation of the erythropoietin receptor, for example, by binding to and causing dimerization of the receptor.
- Erythropoiesis stimulating proteins include erythropoietin and variants, analogs, or derivatives thereof that bind to and activate erythropoietin receptor; antibodies that bind to erythropoietin receptor and activate the receptor; or peptides that bind to and activate erythropoietin receptor.
- Erythropoiesis stimulating proteins include, but are not limited to, epoetin alfa, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and analogs thereof, pegylated erythropoietin, carbamylated erythropoietin, mimetic peptides (including EMP1/hematide), and mimetic antibodies.
- Exemplary erythropoiesis stimulating proteins include erythropoietin, darbepoetin, erythropoietin agonist variants, and peptides or antibodies that bind and activate erythropoietin receptor (and include compounds reported in U.S. Publication Nos. 2003/0215444 and 2006/0040858, the disclosures of each of which is incorporated herein by reference in its entirety) as well as erythropoietin molecules or variants or analogs thereof as disclosed in the following patents or patent applications, which are each herein incorporated by reference in its entirety: U.S. Patent Nos.
- Examples of other pharmaceutical products that may be used with the methods disclosed herein may include, but are not limited to, antibodies such as Vectibix® (panitumumab), XgevaTM (denosumab) and ProliaTM (denosamab); other biological agents such as Enbrel® (etanercept, TNF-receptor / Fc fusion protein, TNF blocker), Neulasta® (pegfilgrastim, pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF), Neupogen® (filgrastim , G-CSF, hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such as Sensipar® (cinacalcet).
- antibodies such as Vectibix® (panitumumab), XgevaTM (denosumab) and ProliaTM (denosamab)
- other biological agents such
- the methods may also be used with a therapeutic antibody, a polypeptide, a protein or other chemical, such as an iron, for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose.
- a therapeutic antibody for example, a polypeptide, a protein or other chemical, such as an iron, for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose.
- the pharmaceutical product may be in liquid form, or reconstituted from lyophilized form.
- proteins are the specific proteins set forth below, including fusions, fragments, analogs, variants or derivatives thereof: OPGL specific antibodies, peptibodies, and related proteins, and the like (also referred to as RANKL specific antibodies, peptibodies and the like), including fully humanized and human OPGL specific antibodies, particularly fully humanized monoclonal antibodies, including but not limited to the antibodies described in PCT Publication No.
- WO 03/002713 which is incorporated herein in its entirety as to OPGL specific antibodies and antibody related proteins, particularly those having the sequences set forth therein, particularly, but not limited to, those denoted therein: 9H7; 18B2; 2D8; 2E11; 16E1; and 22B3, including the OPGL specific antibodies having either the light chain of SEQ ID NO:2 as set forth therein in Figure 2 and/or the heavy chain of SEQ ID NO:4, as set forth therein in Figure 4, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- WO 2004/058988 which are incorporated by reference herein in their entirety particularly in parts pertinent to myostatin specific peptibodies, including but not limited to peptibodies of the mTN8-19 family, including those of SEQ ID NOS:305-351, including TN8-19-1 through TN8-19-40, TN8-19 coni and TN8-19 con2; peptibodies of the mL2 family of SEQ ID NOS:357-383; the mL15 family of SEQ ID NOS:384- 409; the mL17 family of SEQ ID NOS:410-438; the mL20 family of SEQ ID NOS:439-446; the mL21 family of SEQ ID NOS:447- 452; the mL24 family of SEQ ID NOS:453-454; and those of SEQ ID NOS:615-631, each of which is individually and specifically incorporated by reference herein in their entirety fully as disclosed in the foregoing publication; [0085
- Interleukin 1-receptor 1 (“IL1-R1”) specific antibodies, peptibodies, and related proteins, and the like, including but not limited to those described in U.S. Publication No. 2004/097712, which is incorporated herein by reference in its entirety in parts pertinent to IL1-R1 specific binding proteins, monoclonal antibodies in particular, especially, without limitation, those designated therein: 15CA, 26F5, 27F2, 24E12, and 10H7, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the aforementioned publication;
- Ang2 specific antibodies, peptibodies, and related proteins, and the like including but not limited to those described in PCT Publication No. WO 03/057134 and U.S. Publication No. 2003/0229023, each of which is incorporated herein by reference in its entirety particularly in parts pertinent to Ang2 specific antibodies and peptibodies and the like, especially those of sequences described therein and including but not limited to: L1(N); L1(N) WT; L1(N) 1 K WT; 2xL1(N); 2xL1(N) WT; Con4 (N), Con4 (N) 1 K WT, 2xCon4 (N) 1 K; L1C; L1C 1 K; 2xL1C; Con4C; Con4C 1 K; 2xCon4C 1 K; Con4-L1 (N); Con4-L1C; TN-12-9 (N); C17 (N); TN8-8(N); TN8-14 (N); Con 1 (N),
- WO 2003/030833 which is incorporated herein by reference in its entirety as to the same, particularly Ab526; Ab528; Ab531; Ab533; Ab535; Ab536; Ab537; Ab540; Ab543; Ab544; Ab545; Ab546; A551; Ab553; Ab555; Ab558; Ab559; Ab565; AbFIAbFD; AbFE; AbFJ; AbFK; AbG1D4; AbGC1E8; AbH1C12; AblA1 ; AblF; AbIK, AblP; and AblP, in their various permutations as described therein, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- NGF specific antibodies, peptibodies, and related proteins, and the like including, in particular, but not limited to those described in U.S. Publication No. 2005/0074821 and U.S. Patent No. 6,919,426, which are incorporated herein by reference in their entirety particularly as to NGF-specific antibodies and related proteins in this regard, including in particular, but not limited to, the NGF-specific antibodies therein designated 4D4, 4G6, 6H9, 7H2, 14D10 and 14D11, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
- CD22 specific antibodies, peptibodies, and related proteins, and the like such as those described in U.S. Patent No. 5,789,554, which is incorporated herein by reference in its entirety as to CD22 specific antibodies and related proteins, particularly human CD22 specific antibodies, such as but not limited to humanized and fully human antibodies, including but not limited to humanized and fully human monoclonal antibodies, particularly including but not limited to human CD22 specific IgG antibodies, such as, for instance, a dimer of a human-mouse monoclonal hLL2 gamma-chain disulfide linked to a human-mouse monoclonal hLL2 kappa-chain, including, but limited to, for example, the human CD22 specific fully humanized antibody in Epratuzumab, CAS registry number 501423-23-0;
- IGF-1 receptor specific antibodies such as those described in PCT Publication No. WO 06/069202, which is incorporated herein by reference in its entirety as to IGF-1 receptor specific antibodies and related proteins, including but not limited to the IGF-1 specific antibodies therein designated L1 H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L
- anti-IGF-1 R antibodies for use in the methods and compositions of the present invention are each and all of those described in:
- IL-15 specific antibodies, peptibodies, and related proteins, and the like such as, in particular, humanized monoclonal antibodies, particularly antibodies such as those disclosed in U.S. Publication Nos. 2003/0138421; 2003/023586; and 2004/0071702; and U.S. Patent No. 7,153,507, each of which is incorporated herein by reference in its entirety as to IL-15 specific antibodies and related proteins, including peptibodies, including particularly, for instance, but not limited to, HuMax IL-15 antibodies and related proteins, such as, for instance, 146B7;
- IFN gamma specific antibodies peptibodies, and related proteins and the like, especially human IFN gamma specific antibodies, particularly fully human anti-IFN gamma antibodies, such as, for instance, those described in U.S. Publication No. 2005/0004353, which is incorporated herein by reference in its entirety as to IFN gamma specific antibodies, particularly, for example, the antibodies therein designated 1118; 1118*; 1119; 1121; and 1121*.
- Specific antibodies include those having the heavy chain of SEQ ID NO:17 and the light chain of SEQ ID NO:18; those having the heavy chain variable region of SEQ ID NO:6 and the light chain variable region of SEQ ID NO:8; those having the heavy chain of SEQ ID NO:19 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:10 and the light chain variable region of SEQ ID NO:12; those having the heavy chain of SEQ ID NO:32 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:30 and the light chain variable region of SEQ ID NO:12; those having the heavy chain sequence of SEQ ID NO:21 and the light chain sequence of SEQ ID NO:22; those having the heavy chain variable region of SEQ ID NO:14 and the light chain variable region of SEQ ID NO:16; those having the heavy chain of SEQ ID NO:21 and the light chain of SEQ ID NO:33; and those having the heavy chain variable region of SEQ ID NO:14 and the
- TALL-1 specific antibodies such as those described in U.S. Publication Nos. 2003/0195156 and 2006/0135431, each of which is incorporated herein by reference in its entirety as to TALL-1 binding proteins, particularly the molecules of Tables 4 and 5B, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publications;
- PTH Parathyroid hormone
- TPO-R Thrombopoietin receptor
- TRAIL-R2 specific antibodies, peptibodies, related proteins and the like such as those described in U.S. Patent No. 7,521,048, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TRAIL-R2;
- Activin A specific antibodies, peptibodies, related proteins, and the like, including but not limited to those described in U.S. Publication No. 2009/0234106, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind Activin A;
- TGF-beta specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in U.S. Patent No. 6,803,453 and U.S. Publication No. 2007/0110747, each of which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TGF-beta;
- Amyloid-beta protein specific antibodies including but not limited to those described in PCT Publication No. WO 2006/081171, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind amyloid-beta proteins.
- One antibody contemplated is an antibody having a heavy chain variable region comprising SEQ ID NO:8 and a light chain variable region having SEQ ID NO:6 as disclosed in the foregoing publication;
- c-Kit specific antibodies including but not limited to those described in U.S. Publication No. 2007/0253951, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind c-Kit and/or other stem cell factor receptors;
- OX40L specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in U.S. Publication No. 2006/0002929, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind OX40L and/or other ligands of the 0X40 receptor; and
- Activase® (alteplase, tPA); Aranesp® (darbepoetin alfa); Epogen® (epoetin alfa, or erythropoietin); GLP-1, Avonex® (interferon beta-1a); Bexxar® (tositumomab, anti-CD22 monoclonal antibody); Betaseron® (interferon-beta); Campath® (alemtuzumab, anti-CD52 monoclonal antibody); Dynepo® (epoetin delta); Velcade® (bortezomib); MLN0002 (anti- a4b7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel® (etanercept, TNF-receptor /Fc fusion protein, TNF blocker); Eprex® (epoetin alfa);
- LymphoCide® epratuzumab, anti-CD22 mAb
- BenlystaTM lymphostat B, belimumab, anti-BlyS mAb
- Metalyse® tenecteplase, t-PA analog
- Mircera® methoxy polyethylene glycol-epoetin beta
- Mylotarg® gemtuzumab ozogamicin
- efalizumab Cimzia® (certolizumab pegol, CDP 870); SolirisTM (eculizumab); pexelizumab (anti-C5 complement); Numax® (MEDI-524); Lucentis® (ranibizumab); Panorex® (17-1 A, edrecolomab); Trabio® (lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4); Osidem® (IDM-1); OvaRex® (B43.13); Nuvion® (visilizumab); cantuzumab mertansine (huC242- DM1); NeoRecormon® (epoetin beta); Neumega® (oprelvekin, human interleukin-11); Neulasta® (pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G
- Tysabri® natalizumab, anti-a4integrin mAb
- Valortim® MDX-1303, anti-B. anthracis protective antigen mAb
- ABthraxTM Vectibix® (panitumumab); Xolair® (omalizumab); ETI211 (anti-MRSA mAb)
- IL-1 trap the Fc portion of human lgG1 and the extracellular domains of both IL-1 receptor components (the Type I receptor and receptor accessory protein)
- VEGF trap Ig domains of VEGFR1 fused to lgG1 Fc
- Zenapax® diaclizumab
- Zenapax® diaclizumab, anti-IL-2Ra mAb
- Zevalin® ibritumomab tiuxetan
- Zetia® ezetimibe
- Orencia® atacicept, TACI-lg
- sclerostin antibody such as but not limited to romosozumab, blosozumab, or BPS 804 (Novartis).
- therapeutics such as rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX or XGEVA.
- a monoclonal antibody that binds human Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), e.g. U.S. Patent No. 8,030,547, U.S. Publication No.
- talimogene laherparepvec or another oncolytic HSV for the treatment of melanoma or other cancers.
- oncolytic HSV include, but are not limited to talimogene laherparepvec (U.S. Patent Nos. 7,223,593 and 7,537,924); OncoVEXGALV/CD (U.S. Pat. No. 7,981,669); OrienXOIO (Lei et al. (2013), World J. Gastroenterol., 19:5138-5143); G207, 1716; NV1020; NV12023; NV1034 and NV1042 (Vargehes et al. (2002), Cancer Gene Ther., 9(12):967-978).
- TIMPs are endogenous tissue inhibitors of metal loproteinases (TIMPs) and are important in many natural processes.
- TIMP-3 is expressed by various cells or and is present in the extracellular matrix; it inhibits all the major cartilage-degrading metalloproteases, and may play a role in role in many degradative diseases of connective tissue, including rheumatoid arthritis and osteoarthritis, as well as in cancer and cardiovascular conditions.
- the amino acid sequence of TIMP-3, and the nucleic acid sequence of a DNA that encodes TIMP-3 are disclosed in U.S. Patent No. 6,562,596, issued May 13, 2003, the disclosure of which is incorporated by reference herein. Description of TIMP mutations can be found in U.S. Publication No. 2014/0274874 and PCT Publication No. WO 2014/152012.
- CGRP human calcitonin gene-related peptide
- bispecific antibody molecule that target the CGRP receptor and other headache targets. Further information concerning these molecules can be found in PCT Application No. WO 2010/075238.
- bispecific T cell engager (BiTE®) molecules e.g. BLINCYTO® (blinatumomab)
- BLINCYTO® blindatumomab
- APJ large molecule agonist e.g., apelin or analogues thereof in the device.
- Information relating to such molecules can be found in PCT Publication No. WO 2014/099984.
- the medicament comprises a therapeutically effective amount of an anti-thymic stromal lymphopoietin (TSLP) or TSLP receptor antibody.
- TSLP anti-thymic stromal lymphopoietin
- anti-TSLP antibodies that may be used in such embodiments include, but are not limited to, those described in U.S. Patent Nos. 7,982,016, and 8,232,372, and U.S. Publication No. 2009/0186022.
- anti-TSLP receptor antibodies include, but are not limited to, those described in U.S. Patent No. 8,101,182.
- the medicament comprises a therapeutically effective amount of the anti-TSLP antibody designated as A5 within U.S. Patent No. 7,982,016.
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Basic Packing Technique (AREA)
- Filling Of Jars Or Cans And Processes For Cleaning And Sealing Jars (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020237038066A KR20240011135A (ko) | 2021-05-21 | 2022-05-19 | 약물 용기를 위한 충전 레시피를 최적화하는 방법 |
US18/288,549 US20240208680A1 (en) | 2021-05-21 | 2022-05-19 | Method of optimizing a filling recipe for a drug container |
CN202280035596.1A CN117320964A (zh) | 2021-05-21 | 2022-05-19 | 优化药物容器的灌装方案的方法 |
BR112023024278A BR112023024278A2 (pt) | 2021-05-21 | 2022-05-19 | Método de otimizar uma receita de enchimento para um recipiente de fármacos |
MX2023013640A MX2023013640A (es) | 2021-05-21 | 2022-05-19 | Metodo de optimizacion de una receta de llenado para un contenedor de medicamento. |
JP2023569877A JP2024523779A (ja) | 2021-05-21 | 2022-05-19 | 薬物容器用の充填レシピを最適化する方法 |
AU2022279223A AU2022279223A1 (en) | 2021-05-21 | 2022-05-19 | Method of optimizing a filling recipe for a drug container |
IL307418A IL307418A (en) | 2021-05-21 | 2022-05-19 | A method for optimizing a filling recipe for a drug container |
CA3217207A CA3217207A1 (fr) | 2021-05-21 | 2022-05-19 | Procede d'optimisation d'une recette de remplissage pour un recipient de medicament |
EP22731368.1A EP4341161A1 (fr) | 2021-05-21 | 2022-05-19 | Procédé d?optimisation d?une recette de remplissage pour un récipient de médicament |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163191797P | 2021-05-21 | 2021-05-21 | |
US63/191,797 | 2021-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022246055A1 true WO2022246055A1 (fr) | 2022-11-24 |
Family
ID=82100162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/030014 WO2022246055A1 (fr) | 2021-05-21 | 2022-05-19 | Procédé d'optimisation d'une recette de remplissage pour un récipient de médicament |
Country Status (12)
Country | Link |
---|---|
US (1) | US20240208680A1 (fr) |
EP (1) | EP4341161A1 (fr) |
JP (1) | JP2024523779A (fr) |
KR (1) | KR20240011135A (fr) |
CN (1) | CN117320964A (fr) |
AU (1) | AU2022279223A1 (fr) |
BR (1) | BR112023024278A2 (fr) |
CA (1) | CA3217207A1 (fr) |
CL (1) | CL2023003444A1 (fr) |
IL (1) | IL307418A (fr) |
MX (1) | MX2023013640A (fr) |
WO (1) | WO2022246055A1 (fr) |
Citations (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
WO1991005867A1 (fr) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Isoformes d'erythropoietine |
WO1995005465A1 (fr) | 1993-08-17 | 1995-02-23 | Amgen Inc. | Analogues d'erytropoietine |
US5441868A (en) | 1983-12-13 | 1995-08-15 | Kirin-Amgen, Inc. | Production of recombinant erythropoietin |
US5547933A (en) | 1983-12-13 | 1996-08-20 | Kirin-Amgen, Inc. | Production of erythropoietin |
WO1996038557A1 (fr) | 1995-06-02 | 1996-12-05 | Genentech, Inc. | Antagonistes du recepteur du facteur de croissance des hepatocytes et leurs utilisations |
WO1996040772A2 (fr) | 1995-06-07 | 1996-12-19 | Ortho Pharmaceutical Corporation | Dimeres peptidiques d'agonistes |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5789554A (en) | 1994-08-12 | 1998-08-04 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
WO1999066054A2 (fr) | 1998-06-15 | 1999-12-23 | Genzyme Transgenics Corp. | Fusion analogue d'erythropoietine-albumine serique humaine |
US6030086A (en) | 1998-03-02 | 2000-02-29 | Becton, Dickinson And Company | Flash tube reflector with arc guide |
WO2000024893A2 (fr) | 1998-10-23 | 2000-05-04 | Amgen Inc. | Methodes et compositions permettant de prevenir et de traiter l'anemie |
WO2000061637A1 (fr) | 1999-04-14 | 2000-10-19 | Smithkline Beecham Corporation | Anticorps du recepteur d'erythropoietine |
WO2001031007A2 (fr) | 1999-10-22 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee |
WO2001036489A2 (fr) | 1999-11-12 | 2001-05-25 | Merck Patent Gmbh | Formes d'erythropoietine dotees de proprietes ameliorees |
US6310078B1 (en) | 1998-04-20 | 2001-10-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
WO2001081405A2 (fr) | 2000-04-21 | 2001-11-01 | Amgen Inc. | Methodes et compositions destinees a la prevention et au traitement de l'anemie |
WO2002014356A2 (fr) | 2000-08-11 | 2002-02-21 | Baxter Healthcare Sa | Methodes therapeutiques de traitement de sujet avec une erytrhopoietine recombinee presentant une activite elevee et peu d'effets secondaires |
WO2002020034A1 (fr) | 2000-09-08 | 2002-03-14 | Gryphon Therapeutics, Inc. | Ligation chimique 'pseudo'-native |
US6391633B1 (en) | 1997-07-23 | 2002-05-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
WO2002049673A2 (fr) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugues d'erythropoietine |
WO2002085940A2 (fr) | 2001-04-04 | 2002-10-31 | Genodyssee | Polynucleotides et polypeptides du gene de l'erythropoietine (epo) |
WO2003002713A2 (fr) | 2001-06-26 | 2003-01-09 | Abgenix, Inc. | Anticorps opgl |
US20030023586A1 (en) | 2000-03-03 | 2003-01-30 | Super Internet Site System Pty Ltd. | On-line geographical directory |
WO2003029291A2 (fr) | 2001-09-25 | 2003-04-10 | F. Hoffmann-La Roche Ag | Erythropoietine pegylee et diglycosylee |
WO2003030833A2 (fr) | 2001-10-11 | 2003-04-17 | Amgen Inc. | Agents de liaison spécifiques de l'angiopoïétine-2 |
US20030082749A1 (en) | 2001-08-17 | 2003-05-01 | Sun Lee-Hwei K. | Fc fusion proteins of human erythropoietin with increased biological activities |
US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
US6583272B1 (en) | 1999-07-02 | 2003-06-24 | Hoffmann-La Roche Inc. | Erythropoietin conjugates |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
WO2003055526A2 (fr) | 2001-12-21 | 2003-07-10 | Maxygen Aps | Conjugues d'erythropoietine |
WO2003057134A2 (fr) | 2001-10-11 | 2003-07-17 | Amgen, Inc. | Agents de liaison specifiques de l'angiopoietine-2 humaine |
US20030138421A1 (en) | 2001-08-23 | 2003-07-24 | Van De Winkel Jan G.J. | Human Antibodies specific for interleukin 15 (IL-15) |
WO2003059951A2 (fr) | 2002-01-18 | 2003-07-24 | Pierre Fabre Medicament | Anticorps anti-igf-ir et leurs applications |
US20030143202A1 (en) | 2002-01-31 | 2003-07-31 | Binley Katie (Mary) | Anemia |
US20030195156A1 (en) | 2001-05-11 | 2003-10-16 | Amgen Inc. | Peptides and related molecules that bind to TALL-1 |
WO2003084477A2 (fr) | 2002-03-29 | 2003-10-16 | Centocor, Inc. | Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations |
US20030215444A1 (en) | 1994-07-26 | 2003-11-20 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
WO2003094858A2 (fr) | 2002-05-13 | 2003-11-20 | Modigenetech Ltd. | Érythropoïétine comportant une extension ctp |
US20030235582A1 (en) | 2002-06-14 | 2003-12-25 | Immunogen, Inc. | Anti-IGF-I receptor antibody |
WO2004002417A2 (fr) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations |
WO2004002424A2 (fr) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees |
WO2004009627A1 (fr) | 2002-07-19 | 2004-01-29 | Cangene Corporation | Composes erythropoietiques pegyles |
US20040018191A1 (en) | 2002-05-24 | 2004-01-29 | Schering Corporation | Neutralizing human anti-IGFR antibody |
WO2004018667A1 (fr) | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | Peptides et medicaments les contenant |
WO2004024761A1 (fr) | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | Polypeptides-has, notamment, erythropoietine-has ayant subi une acylation |
US20040071702A1 (en) | 2001-08-23 | 2004-04-15 | Genmab, Inc. | Human antibodies specific for interleukin 15 (IL-15) |
US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
WO2004033651A2 (fr) | 2002-10-09 | 2004-04-22 | Neose Technologies, Inc. | Erythropoietine: remodelage et glycoconjugaison d'erythropoietine |
WO2004035603A2 (fr) | 2002-10-14 | 2004-04-29 | Abbott Laboratories | Anticorps se liant au recepteur de l'erythropoietine |
US20040086503A1 (en) | 2001-01-05 | 2004-05-06 | Cohen Bruce D. | Antibodies to insulin-like growth factor I receptor |
US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
US20040097712A1 (en) | 2002-09-06 | 2004-05-20 | Amgen, Inc. A Corporation Of The State Of Delaware | Therapeutic human anti-IL1-R1 monoclonal antibody |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2004058988A2 (fr) | 2002-12-20 | 2004-07-15 | Amgen, Inc. | Agents de liaison inhibant la myostatine |
US20040175379A1 (en) | 2002-10-14 | 2004-09-09 | Devries Peter J. | Erythropoietin receptor binding antibodies |
US6803453B1 (en) | 1998-11-27 | 2004-10-12 | Darwin Discovery Ltd. | Antibodies associated with alterations in bone density |
US20040202655A1 (en) | 2003-03-14 | 2004-10-14 | Morton Phillip A. | Antibodies to IGF-I receptor for the treatment of cancers |
US20040228859A1 (en) | 2003-04-02 | 2004-11-18 | Yvo Graus | Antibodies against insulin-like growth factor 1 receptor and uses thereof |
US20040229318A1 (en) | 2003-05-17 | 2004-11-18 | George Heavner | Erythropoietin conjugate compounds with extended half-lives |
WO2004101611A2 (fr) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Nouveaux peptides se fixant au recepteur de l'erythropoietine |
WO2004101606A2 (fr) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Nouveaux peptides se fixant au recepteur de l'erythropoietine |
WO2004101600A2 (fr) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations |
US6835809B1 (en) | 1998-10-23 | 2004-12-28 | Amgen Inc. | Thrombopoietic compounds |
US20040265307A1 (en) | 2002-06-14 | 2004-12-30 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US20040266690A1 (en) | 2003-05-30 | 2004-12-30 | Chadler Pool | Formation of novel erythropoietin conjugates using transglutaminase |
WO2005001136A1 (fr) | 2003-06-04 | 2005-01-06 | Irm Llc | Methodes et compositions pour la modulation de l'expression de l'erythropoietine |
US20050004353A1 (en) | 2002-10-16 | 2005-01-06 | Amgen, Inc., A Corporation Of The State Of Delaware | Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors |
WO2005001025A2 (fr) | 2003-05-06 | 2005-01-06 | Syntonix Pharmaceuticals, Inc. | Hybrides monomeres/dimeres chimeriques d'immunoglobuline |
US20050008642A1 (en) | 2003-07-10 | 2005-01-13 | Yvo Graus | Antibodies against insulin-like growth factor 1 receptor and uses thereof |
US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
US20050026834A1 (en) | 1999-01-14 | 2005-02-03 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
WO2005016970A2 (fr) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline |
WO2005017107A2 (fr) | 2003-07-18 | 2005-02-24 | Amgen Inc. | Agents de liaison specifiques se liant a un facteur de croissance hepatocyte |
WO2005021579A2 (fr) | 2003-08-28 | 2005-03-10 | Biorexis Pharmaceutical Corporation | Peptides mimetiques epo et proteines de fusion |
WO2005025606A1 (fr) | 2003-09-09 | 2005-03-24 | Warren Pharmaceuticals, Inc. | Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene |
US20050074821A1 (en) | 2003-07-15 | 2005-04-07 | Wild Kenneth D. | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
WO2005032460A2 (fr) | 2003-09-30 | 2005-04-14 | Centocor, Inc. | Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes |
US20050084906A1 (en) | 2002-01-18 | 2005-04-21 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
US20050096461A1 (en) | 1997-07-14 | 2005-05-05 | Bolder Biotechnology, Inc. | Cysteine variants of erythropoietin |
WO2005047331A2 (fr) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Anticorps liant un recepteur de l'interleucine 4 |
WO2005051327A2 (fr) | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Erythropoietine glycopegylee |
US20050124564A1 (en) | 2002-01-31 | 2005-06-09 | Binley Katie M. | Anemia |
US20050136063A1 (en) | 2003-11-21 | 2005-06-23 | Schering Corporation | Anti-IGFR antibody therapeutic combinations |
WO2005058967A2 (fr) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications |
US20050153879A1 (en) | 2002-03-26 | 2005-07-14 | Monica Svetina | Process for the preparation of a desired erythropoietin glyco-isoform profile |
WO2005063809A1 (fr) | 2003-12-22 | 2005-07-14 | Dubai Genetics Fz-Llc | Erythopoietine identique a la forme naturelle |
WO2005063808A1 (fr) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Proteine hybride fc-erythropoietine a pharmacocinetique amelioree |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
US20050158822A1 (en) | 2004-01-20 | 2005-07-21 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5'-UTR |
US20050170457A1 (en) | 2003-12-31 | 2005-08-04 | Chadler Pool | Novel recombinant proteins with N-terminal free thiol |
WO2005070451A1 (fr) | 2004-01-22 | 2005-08-04 | Zafena Aktiebolag | Composition pharmaceutique comprenant une erythropoietine non glycosylee |
US20050181359A1 (en) | 1999-04-15 | 2005-08-18 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
WO2005081687A2 (fr) | 2003-09-30 | 2005-09-09 | Centocor, Inc. | Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes |
WO2005084711A1 (fr) | 2004-03-02 | 2005-09-15 | Chengdu Institute Of Biological Products | Erythropoietine recombinante pegylee a activite in vivo |
US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
WO2005092369A2 (fr) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugues d'hydroxy-ethyl-amidon et d'erythropoietine |
US20050227289A1 (en) | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
WO2005103076A2 (fr) | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Variants d'erythropoietine |
US20060002929A1 (en) | 2004-03-23 | 2006-01-05 | Khare Sanjay D | Monoclonal antibodies |
WO2006002646A2 (fr) | 2004-07-07 | 2006-01-12 | H. Lundbeck A/S | Nouvelle erythropoietine carbamylee et son procede de production |
WO2006013472A2 (fr) | 2004-07-29 | 2006-02-09 | Pierre Fabre Medicament | Nouveaux anticorps anti-igf-ir et utilisations |
US20060040358A1 (en) | 1998-12-03 | 2006-02-23 | Tanja Ligensa | IGF-1 receptor interacting proteins |
WO2006029094A2 (fr) | 2004-09-02 | 2006-03-16 | Xencor, Inc. | Derives d'erythropoietine a antigenicite modifiee |
WO2006050959A2 (fr) | 2004-11-10 | 2006-05-18 | Aplagen Gmbh | Molecules favorisant l'hematopoiese |
US20060111279A1 (en) | 2003-11-24 | 2006-05-25 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
WO2006069202A2 (fr) | 2004-12-22 | 2006-06-29 | Amgen Inc. | Compositions et procedes impliquant des anticorps diriges contre le recepteur igf-1r |
WO2006081171A1 (fr) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Anticorps anti-amyloide humanise |
WO2006138729A2 (fr) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Antagonistes de recepteur pour le traitement de cancer osseux metastatique |
WO2007000328A1 (fr) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations |
WO2007011941A2 (fr) | 2005-07-18 | 2007-01-25 | Amgen Inc. | Anticorps neutralisants anti-b7rp1 humains |
WO2007012614A2 (fr) | 2005-07-22 | 2007-02-01 | Pierre Fabre Medicament | Nouveaux anticorps anti igf-ir et leur utilisation |
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
US20070110747A1 (en) | 2005-05-03 | 2007-05-17 | Ucb S.A. | Binding agents |
US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
US7271689B1 (en) | 2000-11-22 | 2007-09-18 | Fonar Corporation | Magnet structure |
US20070253951A1 (en) | 2006-04-24 | 2007-11-01 | Gordon Ng | Humanized c-Kit antibody |
WO2007136752A2 (fr) | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Compositions d'érythropoïétine |
WO2008057458A2 (fr) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonistes de pcsk9 |
WO2008057459A2 (fr) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonistes de pcsk9 |
WO2008057457A2 (fr) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonistes de pcsk9 |
WO2008125623A2 (fr) | 2007-04-13 | 2008-10-23 | Novartis Ag | Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) |
WO2008133647A2 (fr) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonistes de pcsk9 |
US7521048B2 (en) | 2005-08-31 | 2009-04-21 | Amgen Inc. | TRAIL receptor-2 polypeptides and antibodies |
WO2009055783A2 (fr) | 2007-10-26 | 2009-04-30 | Schering Corporation | Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol |
US20090186022A1 (en) | 2006-02-23 | 2009-07-23 | Novartis Ag | Organic Compounds |
WO2009100297A1 (fr) | 2008-02-07 | 2009-08-13 | Merck & Co., Inc. | Antagonistes de pcsk9 1d05 |
WO2009100318A1 (fr) | 2008-02-07 | 2009-08-13 | Merck & Co., Inc. | Antagonistes de 1b20 pcsk9 |
US20090234106A1 (en) | 2006-09-08 | 2009-09-17 | Amgen Inc. | Anti-activin a antibodies and uses thereof |
WO2010029513A2 (fr) | 2008-09-12 | 2010-03-18 | Rinat Neuroscience Corporation | Antagonistes de pcsk9 |
WO2010075238A1 (fr) | 2008-12-23 | 2010-07-01 | Amgen Inc. | Protéines de liaison au récepteur cgrp humain |
WO2010077854A1 (fr) | 2008-12-15 | 2010-07-08 | Regeneron Pharamaceuticals, Inc. | Anticorps humains à grande affinité contre pcsk9 |
WO2011037791A1 (fr) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonistes de pcsk9 |
WO2011053759A1 (fr) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes |
WO2011053783A2 (fr) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Antagonistes et variants ax213 et ax132 pcsk9 |
WO2011072263A1 (fr) | 2009-12-11 | 2011-06-16 | Irm Llc | Antagonistes de pcsk9 |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
US7981669B2 (en) | 2003-07-25 | 2011-07-19 | Biovex Limited | Viral vectors |
WO2011111007A2 (fr) | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | Anticorps présentant une liaison à l'antigène dépendante du ph |
US8030547B2 (en) | 2002-03-29 | 2011-10-04 | Kumiai Chemical Industry Co., Ltd. | Gene coding for acetolactate synthase |
US8101182B2 (en) | 2007-06-20 | 2012-01-24 | Novartis Ag | Methods and compositions for treating allergic diseases |
WO2012054438A1 (fr) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
WO2012088313A1 (fr) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anticorps anti-pcsk9 et procédés d'utilisation |
US8232372B2 (en) | 2006-12-14 | 2012-07-31 | Schering Corp. | Engineered anti-TSLP antibody |
WO2012101253A1 (fr) | 2011-01-28 | 2012-08-02 | Sanofi | Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9 |
WO2012109530A1 (fr) | 2011-02-11 | 2012-08-16 | Irm Llc | Antagonistes de pcsk9 |
US20130064825A1 (en) | 2011-05-10 | 2013-03-14 | Amgen Inc. | Methods of treating or preventing cholesterol related disorders |
WO2014099984A1 (fr) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Agonistes du récepteur apj et leurs utilisations |
US20140274874A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
WO2014152012A2 (fr) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Variants d'inhibiteur tissulaire de la métalloprotéinase type iii (timp-3), compositions et procédés |
US20190344257A1 (en) * | 2011-07-22 | 2019-11-14 | Vanrx Pharmasystems Inc. | Fill needle system |
-
2022
- 2022-05-19 IL IL307418A patent/IL307418A/en unknown
- 2022-05-19 MX MX2023013640A patent/MX2023013640A/es unknown
- 2022-05-19 BR BR112023024278A patent/BR112023024278A2/pt unknown
- 2022-05-19 WO PCT/US2022/030014 patent/WO2022246055A1/fr active Application Filing
- 2022-05-19 AU AU2022279223A patent/AU2022279223A1/en active Pending
- 2022-05-19 JP JP2023569877A patent/JP2024523779A/ja active Pending
- 2022-05-19 CN CN202280035596.1A patent/CN117320964A/zh active Pending
- 2022-05-19 KR KR1020237038066A patent/KR20240011135A/ko unknown
- 2022-05-19 US US18/288,549 patent/US20240208680A1/en active Pending
- 2022-05-19 EP EP22731368.1A patent/EP4341161A1/fr active Pending
- 2022-05-19 CA CA3217207A patent/CA3217207A1/fr active Pending
-
2023
- 2023-11-20 CL CL2023003444A patent/CL2023003444A1/es unknown
Patent Citations (204)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618698A (en) | 1983-12-13 | 1997-04-08 | Kirin-Amgen, Inc. | Production of erythropoietin |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
US5955422A (en) | 1983-12-13 | 1999-09-21 | Kirin-Amgen, Inc. | Production of erthropoietin |
US5441868A (en) | 1983-12-13 | 1995-08-15 | Kirin-Amgen, Inc. | Production of recombinant erythropoietin |
US5547933A (en) | 1983-12-13 | 1996-08-20 | Kirin-Amgen, Inc. | Production of erythropoietin |
US5756349A (en) | 1983-12-13 | 1998-05-26 | Amgen Inc. | Production of erythropoietin |
US5621080A (en) | 1983-12-13 | 1997-04-15 | Kirin-Amgen, Inc. | Production of erythropoietin |
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
WO1991005867A1 (fr) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Isoformes d'erythropoietine |
US5856298A (en) | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
WO1995005465A1 (fr) | 1993-08-17 | 1995-02-23 | Amgen Inc. | Analogues d'erytropoietine |
US6562596B1 (en) | 1993-10-06 | 2003-05-13 | Amgen Inc. | Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods |
US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5986047A (en) | 1993-11-19 | 1999-11-16 | Affymax Technologies N.V. | Peptides that bind to the erythropoietin receptor |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US20030215444A1 (en) | 1994-07-26 | 2003-11-20 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5789554A (en) | 1994-08-12 | 1998-08-04 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
WO1996038557A1 (fr) | 1995-06-02 | 1996-12-05 | Genentech, Inc. | Antagonistes du recepteur du facteur de croissance des hepatocytes et leurs utilisations |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US6468529B1 (en) | 1995-06-02 | 2002-10-22 | Genentech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
WO1996040772A2 (fr) | 1995-06-07 | 1996-12-19 | Ortho Pharmaceutical Corporation | Dimeres peptidiques d'agonistes |
US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
US20050107591A1 (en) | 1997-07-14 | 2005-05-19 | Bolder Biotechnology, Inc. | Cysteine variants of erythropoietin |
US20050096461A1 (en) | 1997-07-14 | 2005-05-05 | Bolder Biotechnology, Inc. | Cysteine variants of erythropoietin |
US6391633B1 (en) | 1997-07-23 | 2002-05-21 | Roche Diagnostics Gmbh | Production of erythropoietin by endogenous gene activation |
US6030086A (en) | 1998-03-02 | 2000-02-29 | Becton, Dickinson And Company | Flash tube reflector with arc guide |
US6310078B1 (en) | 1998-04-20 | 2001-10-30 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
US20040248815A1 (en) | 1998-04-20 | 2004-12-09 | Ortho Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
US6750369B2 (en) | 1998-04-20 | 2004-06-15 | Ortho Mcneil Pharmaceutical, Inc. | Substituted amino acids as erythropoietin mimetics |
WO1999066054A2 (fr) | 1998-06-15 | 1999-12-23 | Genzyme Transgenics Corp. | Fusion analogue d'erythropoietine-albumine serique humaine |
US20040143857A1 (en) | 1998-06-15 | 2004-07-22 | Michael Young | Erythropoietin analog-human serum albumin fusion |
US20020155998A1 (en) | 1998-06-15 | 2002-10-24 | Genzyme Transgenics Corporation, A Massachusetts Corporation | Erythropoietin analog-human serum albumin fusion |
US20050158832A1 (en) | 1998-06-15 | 2005-07-21 | Michael Young | Erythropoietin analog-human serum albumin fusion |
US6835809B1 (en) | 1998-10-23 | 2004-12-28 | Amgen Inc. | Thrombopoietic compounds |
WO2000024893A2 (fr) | 1998-10-23 | 2000-05-04 | Amgen Inc. | Methodes et compositions permettant de prevenir et de traiter l'anemie |
US6803453B1 (en) | 1998-11-27 | 2004-10-12 | Darwin Discovery Ltd. | Antibodies associated with alterations in bone density |
US20060040358A1 (en) | 1998-12-03 | 2006-02-23 | Tanja Ligensa | IGF-1 receptor interacting proteins |
US20050026834A1 (en) | 1999-01-14 | 2005-02-03 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US20050244409A1 (en) | 1999-04-14 | 2005-11-03 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
WO2000061637A1 (fr) | 1999-04-14 | 2000-10-19 | Smithkline Beecham Corporation | Anticorps du recepteur d'erythropoietine |
US20050181359A1 (en) | 1999-04-15 | 2005-08-18 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US6583272B1 (en) | 1999-07-02 | 2003-06-24 | Hoffmann-La Roche Inc. | Erythropoietin conjugates |
WO2001031007A2 (fr) | 1999-10-22 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee |
US20050202538A1 (en) | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
WO2001036489A2 (fr) | 1999-11-12 | 2001-05-25 | Merck Patent Gmbh | Formes d'erythropoietine dotees de proprietes ameliorees |
US7537924B2 (en) | 2000-01-21 | 2009-05-26 | Biovex Limited | Virus strains |
US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
US20030023586A1 (en) | 2000-03-03 | 2003-01-30 | Super Internet Site System Pty Ltd. | On-line geographical directory |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
WO2001081405A2 (fr) | 2000-04-21 | 2001-11-01 | Amgen Inc. | Methodes et compositions destinees a la prevention et au traitement de l'anemie |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2002014356A2 (fr) | 2000-08-11 | 2002-02-21 | Baxter Healthcare Sa | Methodes therapeutiques de traitement de sujet avec une erytrhopoietine recombinee presentant une activite elevee et peu d'effets secondaires |
WO2002020034A1 (fr) | 2000-09-08 | 2002-03-14 | Gryphon Therapeutics, Inc. | Ligation chimique 'pseudo'-native |
WO2002019963A2 (fr) | 2000-09-08 | 2002-03-14 | Gryphon Therapeutics, Inc. | Protéines de synthèse stimulant l'érythropoïèse |
US7271689B1 (en) | 2000-11-22 | 2007-09-18 | Fonar Corporation | Magnet structure |
WO2002049673A2 (fr) | 2000-12-20 | 2002-06-27 | F. Hoffmann-La Roche Ag | Conjugues d'erythropoietine |
US7037498B2 (en) | 2001-01-05 | 2006-05-02 | Abgenix, Inc. | Antibodies to insulin-like growth factor I receptor |
US20050244408A1 (en) | 2001-01-05 | 2005-11-03 | Cohen Bruce D | Antibodies to insulin-like growth factor I receptor |
US20040086503A1 (en) | 2001-01-05 | 2004-05-06 | Cohen Bruce D. | Antibodies to insulin-like growth factor I receptor |
WO2002085940A2 (fr) | 2001-04-04 | 2002-10-31 | Genodyssee | Polynucleotides et polypeptides du gene de l'erythropoietine (epo) |
US20060135431A1 (en) | 2001-05-11 | 2006-06-22 | Amgen Inc. | Peptides and related molecules that bind to TALL-1 |
US20030195156A1 (en) | 2001-05-11 | 2003-10-16 | Amgen Inc. | Peptides and related molecules that bind to TALL-1 |
WO2003002713A2 (fr) | 2001-06-26 | 2003-01-09 | Abgenix, Inc. | Anticorps opgl |
US20040175824A1 (en) | 2001-08-17 | 2004-09-09 | Sun Lee-Hwei K. | Fc fusion proteins of human erythropoietin with high biological activities |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US20050124045A1 (en) | 2001-08-17 | 2005-06-09 | Sun Lee-Hwei K. | Fc fusion proteins of human erythropoietin with increased biological activities |
US20050142642A1 (en) | 2001-08-17 | 2005-06-30 | Sun Lee-Hwei K. | Fc fusion proteins of human erythropoietin with increased biological activities |
US20030082749A1 (en) | 2001-08-17 | 2003-05-01 | Sun Lee-Hwei K. | Fc fusion proteins of human erythropoietin with increased biological activities |
US7030226B2 (en) | 2001-08-17 | 2006-04-18 | Sun Lee-Hwei K | Fc fusion proteins of human erythropoietin with increased biological activities |
US20040071702A1 (en) | 2001-08-23 | 2004-04-15 | Genmab, Inc. | Human antibodies specific for interleukin 15 (IL-15) |
US20030138421A1 (en) | 2001-08-23 | 2003-07-24 | Van De Winkel Jan G.J. | Human Antibodies specific for interleukin 15 (IL-15) |
US7153507B2 (en) | 2001-08-23 | 2006-12-26 | Genmab A/S | Human antibodies specific for interleukin 15 (IL-15) |
WO2003029291A2 (fr) | 2001-09-25 | 2003-04-10 | F. Hoffmann-La Roche Ag | Erythropoietine pegylee et diglycosylee |
US20030077753A1 (en) | 2001-09-25 | 2003-04-24 | Wilhelm Tischer | Diglycosylated erythropoietin |
US20060088906A1 (en) | 2001-10-10 | 2006-04-27 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US20030229023A1 (en) | 2001-10-11 | 2003-12-11 | Oliner Jonathan Daniel | Specific binding agents of human angiopoietin-2 |
WO2003057134A2 (fr) | 2001-10-11 | 2003-07-17 | Amgen, Inc. | Agents de liaison specifiques de l'angiopoietine-2 humaine |
WO2003030833A2 (fr) | 2001-10-11 | 2003-04-17 | Amgen Inc. | Agents de liaison spécifiques de l'angiopoïétine-2 |
WO2003055526A2 (fr) | 2001-12-21 | 2003-07-10 | Maxygen Aps | Conjugues d'erythropoietine |
US20050084906A1 (en) | 2002-01-18 | 2005-04-21 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
WO2003059951A2 (fr) | 2002-01-18 | 2003-07-24 | Pierre Fabre Medicament | Anticorps anti-igf-ir et leurs applications |
US20050124564A1 (en) | 2002-01-31 | 2005-06-09 | Binley Katie M. | Anemia |
US20030143202A1 (en) | 2002-01-31 | 2003-07-31 | Binley Katie (Mary) | Anemia |
US20050153879A1 (en) | 2002-03-26 | 2005-07-14 | Monica Svetina | Process for the preparation of a desired erythropoietin glyco-isoform profile |
US8030547B2 (en) | 2002-03-29 | 2011-10-04 | Kumiai Chemical Industry Co., Ltd. | Gene coding for acetolactate synthase |
WO2003084477A2 (fr) | 2002-03-29 | 2003-10-16 | Centocor, Inc. | Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations |
WO2003094858A2 (fr) | 2002-05-13 | 2003-11-20 | Modigenetech Ltd. | Érythropoïétine comportant une extension ctp |
US20040009902A1 (en) | 2002-05-13 | 2004-01-15 | Irving Boime | CTP extended erythropoietin |
US20040018191A1 (en) | 2002-05-24 | 2004-01-29 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US20040265307A1 (en) | 2002-06-14 | 2004-12-30 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US20050249728A1 (en) | 2002-06-14 | 2005-11-10 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US20030235582A1 (en) | 2002-06-14 | 2003-12-25 | Immunogen, Inc. | Anti-IGF-I receptor antibody |
US20050186203A1 (en) | 2002-06-14 | 2005-08-25 | Immunogen Inc. | Anti-IGF-I receptor antibody |
WO2004002417A2 (fr) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations |
WO2004002424A2 (fr) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees |
WO2004009627A1 (fr) | 2002-07-19 | 2004-01-29 | Cangene Corporation | Composes erythropoietiques pegyles |
WO2004018667A1 (fr) | 2002-08-26 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | Peptides et medicaments les contenant |
US20040097712A1 (en) | 2002-09-06 | 2004-05-20 | Amgen, Inc. A Corporation Of The State Of Delaware | Therapeutic human anti-IL1-R1 monoclonal antibody |
WO2004024761A1 (fr) | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | Polypeptides-has, notamment, erythropoietine-has ayant subi une acylation |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
WO2004033651A2 (fr) | 2002-10-09 | 2004-04-22 | Neose Technologies, Inc. | Erythropoietine: remodelage et glycoconjugaison d'erythropoietine |
US20040071694A1 (en) | 2002-10-14 | 2004-04-15 | Devries Peter J. | Erythropoietin receptor binding antibodies |
US20040175379A1 (en) | 2002-10-14 | 2004-09-09 | Devries Peter J. | Erythropoietin receptor binding antibodies |
WO2004035603A2 (fr) | 2002-10-14 | 2004-04-29 | Abbott Laboratories | Anticorps se liant au recepteur de l'erythropoietine |
US20050004353A1 (en) | 2002-10-16 | 2005-01-06 | Amgen, Inc., A Corporation Of The State Of Delaware | Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors |
US20040091961A1 (en) | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
US20040157293A1 (en) | 2002-11-08 | 2004-08-12 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
WO2004043382A2 (fr) | 2002-11-08 | 2004-05-27 | Egea Biosciences, Inc. | Variants ameliores de l'erythropoietine et methodes d'utilisation |
US20040181033A1 (en) | 2002-12-20 | 2004-09-16 | Hq Han | Binding agents which inhibit myostatin |
WO2004058988A2 (fr) | 2002-12-20 | 2004-07-15 | Amgen, Inc. | Agents de liaison inhibant la myostatine |
US20040202655A1 (en) | 2003-03-14 | 2004-10-14 | Morton Phillip A. | Antibodies to IGF-I receptor for the treatment of cancers |
US20040228859A1 (en) | 2003-04-02 | 2004-11-18 | Yvo Graus | Antibodies against insulin-like growth factor 1 receptor and uses thereof |
US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
WO2005016970A2 (fr) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline |
WO2005001025A2 (fr) | 2003-05-06 | 2005-01-06 | Syntonix Pharmaceuticals, Inc. | Hybrides monomeres/dimeres chimeriques d'immunoglobuline |
WO2004101600A2 (fr) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations |
US20060040858A1 (en) | 2003-05-12 | 2006-02-23 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
US7084245B2 (en) | 2003-05-12 | 2006-08-01 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
WO2004101606A2 (fr) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Nouveaux peptides se fixant au recepteur de l'erythropoietine |
US20050137329A1 (en) | 2003-05-12 | 2005-06-23 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
WO2004101611A2 (fr) | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Nouveaux peptides se fixant au recepteur de l'erythropoietine |
US20050107297A1 (en) | 2003-05-12 | 2005-05-19 | Holmes Christopher P. | Novel poly(ethylene glycol) modified compounds and uses thereof |
WO2004106373A1 (fr) | 2003-05-17 | 2004-12-09 | Centocor, Inc. | Composes conjugues d'erythropoietine a demi-vies rallongees |
US20040229318A1 (en) | 2003-05-17 | 2004-11-18 | George Heavner | Erythropoietin conjugate compounds with extended half-lives |
US20040266690A1 (en) | 2003-05-30 | 2004-12-30 | Chadler Pool | Formation of novel erythropoietin conjugates using transglutaminase |
WO2005001136A1 (fr) | 2003-06-04 | 2005-01-06 | Irm Llc | Methodes et compositions pour la modulation de l'expression de l'erythropoietine |
US20050008642A1 (en) | 2003-07-10 | 2005-01-13 | Yvo Graus | Antibodies against insulin-like growth factor 1 receptor and uses thereof |
US20050074821A1 (en) | 2003-07-15 | 2005-04-07 | Wild Kenneth D. | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
WO2005017107A2 (fr) | 2003-07-18 | 2005-02-24 | Amgen Inc. | Agents de liaison specifiques se liant a un facteur de croissance hepatocyte |
US20050118643A1 (en) | 2003-07-18 | 2005-06-02 | Burgess Teresa L. | Specific binding agents to hepatocyte growth factor |
US20050019914A1 (en) | 2003-07-24 | 2005-01-27 | Aventis Pharma Deutschland Gmbh | Perfusion process for producing erythropoietin |
US7981669B2 (en) | 2003-07-25 | 2011-07-19 | Biovex Limited | Viral vectors |
WO2005021579A2 (fr) | 2003-08-28 | 2005-03-10 | Biorexis Pharmaceutical Corporation | Peptides mimetiques epo et proteines de fusion |
WO2005025606A1 (fr) | 2003-09-09 | 2005-03-24 | Warren Pharmaceuticals, Inc. | Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene |
WO2005032460A2 (fr) | 2003-09-30 | 2005-04-14 | Centocor, Inc. | Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes |
WO2005081687A2 (fr) | 2003-09-30 | 2005-09-09 | Centocor, Inc. | Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes |
US20050112694A1 (en) | 2003-11-07 | 2005-05-26 | Carter Paul J. | Antibodies that bind interleukin-4 receptor |
WO2005047331A2 (fr) | 2003-11-07 | 2005-05-26 | Immunex Corporation | Anticorps liant un recepteur de l'interleucine 4 |
US20050136063A1 (en) | 2003-11-21 | 2005-06-23 | Schering Corporation | Anti-IGFR antibody therapeutic combinations |
US20060111279A1 (en) | 2003-11-24 | 2006-05-25 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
WO2005051327A2 (fr) | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Erythropoietine glycopegylee |
US20050143292A1 (en) | 2003-11-24 | 2005-06-30 | Defrees Shawn | Glycopegylated erythropoietin |
WO2005058967A2 (fr) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications |
WO2005063809A1 (fr) | 2003-12-22 | 2005-07-14 | Dubai Genetics Fz-Llc | Erythopoietine identique a la forme naturelle |
WO2005063808A1 (fr) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Proteine hybride fc-erythropoietine a pharmacocinetique amelioree |
US20050170457A1 (en) | 2003-12-31 | 2005-08-04 | Chadler Pool | Novel recombinant proteins with N-terminal free thiol |
US20050192211A1 (en) | 2003-12-31 | 2005-09-01 | Emd Lexigen Research Center Corp. | Fc-erythropoietin fusion protein with improved pharmacokinetics |
US20050158822A1 (en) | 2004-01-20 | 2005-07-21 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5'-UTR |
WO2005070451A1 (fr) | 2004-01-22 | 2005-08-04 | Zafena Aktiebolag | Composition pharmaceutique comprenant une erythropoietine non glycosylee |
US20050181482A1 (en) | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
WO2005084711A1 (fr) | 2004-03-02 | 2005-09-15 | Chengdu Institute Of Biological Products | Erythropoietine recombinante pegylee a activite in vivo |
WO2005092369A2 (fr) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugues d'hydroxy-ethyl-amidon et d'erythropoietine |
US20060002929A1 (en) | 2004-03-23 | 2006-01-05 | Khare Sanjay D | Monoclonal antibodies |
WO2005100403A2 (fr) | 2004-04-09 | 2005-10-27 | Abbott Laboratories | Anticorps diriges contre le recepteur de l'erythropoietine et utilisations associees |
US20050227289A1 (en) | 2004-04-09 | 2005-10-13 | Reilly Edward B | Antibodies to erythropoietin receptor and uses thereof |
WO2005103076A2 (fr) | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Variants d'erythropoietine |
WO2006002646A2 (fr) | 2004-07-07 | 2006-01-12 | H. Lundbeck A/S | Nouvelle erythropoietine carbamylee et son procede de production |
WO2006013472A2 (fr) | 2004-07-29 | 2006-02-09 | Pierre Fabre Medicament | Nouveaux anticorps anti-igf-ir et utilisations |
WO2006029094A2 (fr) | 2004-09-02 | 2006-03-16 | Xencor, Inc. | Derives d'erythropoietine a antigenicite modifiee |
WO2006050959A2 (fr) | 2004-11-10 | 2006-05-18 | Aplagen Gmbh | Molecules favorisant l'hematopoiese |
WO2006069202A2 (fr) | 2004-12-22 | 2006-06-29 | Amgen Inc. | Compositions et procedes impliquant des anticorps diriges contre le recepteur igf-1r |
WO2006081171A1 (fr) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Anticorps anti-amyloide humanise |
US20070110747A1 (en) | 2005-05-03 | 2007-05-17 | Ucb S.A. | Binding agents |
WO2006138729A2 (fr) | 2005-06-17 | 2006-12-28 | Imclone Systems Incorporated | Antagonistes de recepteur pour le traitement de cancer osseux metastatique |
WO2007000328A1 (fr) | 2005-06-27 | 2007-01-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations |
WO2007011941A2 (fr) | 2005-07-18 | 2007-01-25 | Amgen Inc. | Anticorps neutralisants anti-b7rp1 humains |
US20080166352A1 (en) | 2005-07-18 | 2008-07-10 | Amgen Inc. | Human anti-B7RP1 Neutralizing Antibodies |
WO2007012614A2 (fr) | 2005-07-22 | 2007-02-01 | Pierre Fabre Medicament | Nouveaux anticorps anti igf-ir et leur utilisation |
US7521048B2 (en) | 2005-08-31 | 2009-04-21 | Amgen Inc. | TRAIL receptor-2 polypeptides and antibodies |
US20090186022A1 (en) | 2006-02-23 | 2009-07-23 | Novartis Ag | Organic Compounds |
US20070253951A1 (en) | 2006-04-24 | 2007-11-01 | Gordon Ng | Humanized c-Kit antibody |
WO2007136752A2 (fr) | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Compositions d'érythropoïétine |
US20090234106A1 (en) | 2006-09-08 | 2009-09-17 | Amgen Inc. | Anti-activin a antibodies and uses thereof |
WO2008133647A2 (fr) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonistes de pcsk9 |
WO2008063382A2 (fr) | 2006-11-07 | 2008-05-29 | Merck & Co., Inc. | Antagonistes de pcsk9 |
WO2008057458A2 (fr) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonistes de pcsk9 |
WO2008057457A2 (fr) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonistes de pcsk9 |
WO2008057459A2 (fr) | 2006-11-07 | 2008-05-15 | Merck & Co., Inc. | Antagonistes de pcsk9 |
US8232372B2 (en) | 2006-12-14 | 2012-07-31 | Schering Corp. | Engineered anti-TSLP antibody |
WO2008125623A2 (fr) | 2007-04-13 | 2008-10-23 | Novartis Ag | Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9) |
US8101182B2 (en) | 2007-06-20 | 2012-01-24 | Novartis Ag | Methods and compositions for treating allergic diseases |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
WO2009055783A2 (fr) | 2007-10-26 | 2009-04-30 | Schering Corporation | Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol |
WO2009100318A1 (fr) | 2008-02-07 | 2009-08-13 | Merck & Co., Inc. | Antagonistes de 1b20 pcsk9 |
WO2009100297A1 (fr) | 2008-02-07 | 2009-08-13 | Merck & Co., Inc. | Antagonistes de pcsk9 1d05 |
WO2010029513A2 (fr) | 2008-09-12 | 2010-03-18 | Rinat Neuroscience Corporation | Antagonistes de pcsk9 |
WO2010077854A1 (fr) | 2008-12-15 | 2010-07-08 | Regeneron Pharamaceuticals, Inc. | Anticorps humains à grande affinité contre pcsk9 |
WO2010075238A1 (fr) | 2008-12-23 | 2010-07-01 | Amgen Inc. | Protéines de liaison au récepteur cgrp humain |
WO2011037791A1 (fr) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonistes de pcsk9 |
WO2011053759A1 (fr) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes |
WO2011053783A2 (fr) | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Antagonistes et variants ax213 et ax132 pcsk9 |
WO2011072263A1 (fr) | 2009-12-11 | 2011-06-16 | Irm Llc | Antagonistes de pcsk9 |
WO2011111007A2 (fr) | 2010-03-11 | 2011-09-15 | Rinat Neuroscience Corporation | Anticorps présentant une liaison à l'antigène dépendante du ph |
WO2012054438A1 (fr) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
WO2012088313A1 (fr) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anticorps anti-pcsk9 et procédés d'utilisation |
WO2012101253A1 (fr) | 2011-01-28 | 2012-08-02 | Sanofi | Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9 |
WO2012101251A1 (fr) | 2011-01-28 | 2012-08-02 | Sanofi | Anticorps humains dirigés contre la pcsk9 destinés à être utilisés dans des procédés de traitement basés sur des schémas posologiques particuliers |
WO2012101252A2 (fr) | 2011-01-28 | 2012-08-02 | Sanofi | Anticorps humains contre pcsk9 pour utilisation dans des procédés de traitement de groupes particuliers de sujets |
WO2012109530A1 (fr) | 2011-02-11 | 2012-08-16 | Irm Llc | Antagonistes de pcsk9 |
US20130064825A1 (en) | 2011-05-10 | 2013-03-14 | Amgen Inc. | Methods of treating or preventing cholesterol related disorders |
US20190344257A1 (en) * | 2011-07-22 | 2019-11-14 | Vanrx Pharmasystems Inc. | Fill needle system |
WO2014099984A1 (fr) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Agonistes du récepteur apj et leurs utilisations |
US20140274874A1 (en) | 2013-03-14 | 2014-09-18 | Amgen Inc. | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods |
WO2014152012A2 (fr) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Variants d'inhibiteur tissulaire de la métalloprotéinase type iii (timp-3), compositions et procédés |
Non-Patent Citations (7)
Title |
---|
CAS, no. 501423-23-0 |
COHEN ET AL., CLINICAL CANCER RES., vol. 11, 2005, pages 2063 - 2073 |
LEI ET AL., WORLD J. GASTROENTEROL., vol. 19, 2013, pages 5138 - 5143 |
LU ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 2856 - 2865 |
MALONEY ET AL., CANCER RES., vol. 63, 2003, pages 5073 - 5083 |
THAKUR ET AL., MOL. IMMUNOL., vol. 36, 1999, pages 1107 - 1115 |
VARGEHES ET AL., CANCER GENE THER., vol. 9, no. 12, 2002, pages 967 - 978 |
Also Published As
Publication number | Publication date |
---|---|
JP2024523779A (ja) | 2024-07-02 |
US20240208680A1 (en) | 2024-06-27 |
KR20240011135A (ko) | 2024-01-25 |
IL307418A (en) | 2023-12-01 |
CN117320964A (zh) | 2023-12-29 |
CL2023003444A1 (es) | 2024-07-12 |
AU2022279223A1 (en) | 2023-10-19 |
BR112023024278A2 (pt) | 2024-01-30 |
MX2023013640A (es) | 2023-11-30 |
CA3217207A1 (fr) | 2022-11-24 |
EP4341161A1 (fr) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210361869A1 (en) | Injector and method of assembly | |
US11305056B2 (en) | Needle insertion-retraction system having dual torsion spring system | |
US11957883B2 (en) | Plunger rod and syringe assembly system and method | |
US11285266B2 (en) | Drug delivery device having minimized risk of component fracture upon impact events | |
AU2015284463B2 (en) | Autoinjector with low energy plunger loading | |
TWI846741B (zh) | 用於藥物遞送裝置之平台組裝方法 | |
US12109389B2 (en) | Fluid path assembly for a drug delivery device | |
JP7510952B2 (ja) | シリンジ滅菌確認アセンブリ及び方法 | |
US20240208680A1 (en) | Method of optimizing a filling recipe for a drug container | |
US20220031939A1 (en) | Drug delivery devices with partial drug delivery member retraction | |
CA3170808A1 (fr) | Seringue a distribution controlee | |
US11213620B2 (en) | Drug delivery devices with partial drug delivery member retraction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22731368 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022279223 Country of ref document: AU Ref document number: 2022279223 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 307418 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3217207 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022279223 Country of ref document: AU Date of ref document: 20220519 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18288549 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023569877 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280035596.1 Country of ref document: CN Ref document number: MX/A/2023/013640 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023024278 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202393224 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022731368 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022731368 Country of ref document: EP Effective date: 20231221 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11202308830Y Country of ref document: SG |
|
ENP | Entry into the national phase |
Ref document number: 112023024278 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231121 |